 
Document Type:  Study Protocol 
Official Title:  Multi- center, open -label, uncontrolled study to assess 
contraceptive efficacy and safety of  Mirena during extended 
use beyond [ADDRESS_997268] on heavy menstrual bleeding 
Study ID: [REMOVED] 
Document Date:  20-Sep-2017 
 
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 1of [ADDRESS_997269] on heavy  menstrual bleeding
This protocol version is an integration of the following documents / sections:
1.Original protocol, 
Version 1.0, dated 03 A UG2016
2.Amendment 1(described in Section 15.1)
forming integrated protocol Version 2.0, dated 20SEP 2017
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 4of 119
Signature [CONTACT_9000]
[INVESTIGATOR_507911].
Name:   
[CONTACT_23682]:
Date: Signature:
[CONTACT_9001][INVESTIGATOR_8912]’s study  file and in the 
respective center’s investigator site file.
In the integrated protocol document, this page may  remain unsigned.
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 5of [ADDRESS_997270] on heavy menstrual bleeding
Short title Mirena ExtendedTrial
Acronym MET
Clinical study phase 3
Study objective s Primary objective of the study is to assess the contraceptive efficacy of 
Mirena beyond 5 years up to 8 years of use.
Secondary objectives for the study are the assessment of menstrual blood 
loss (in women that had Mirena inserted for the indication heavy menstrual 
bleeding [HMB]) and safety.
Further objectives are the population pharmacokinetic evaluation of LNG 
plasma concentration data and evaluation of user satisfaction.
Test drug Mirena ,levonorgestrel -releasing intrauterine system
Nam e of active ingredient Levonorgestrel (LNG)
Dose Initial release rate: 20 µg per day
Route of administration Intrauterine
Duration of treatm ent Up to 3 years (total use of the current Mirena up to 8 years)
Reference drug None
Indication Intrauterine contraception
Treatment of heavy menstrual bleeding for w omen who choose to use 
intrauterine contraception as their method of contraception.
Diagnosis and main criteria for 
inclusion /exclusionFertile age women (18 to 35 years at the time o f the screening visit) 
currently using a Mirena for contraception or for contraception and heavy 
menstrual bleeding and who have had the Mirena in situ for at least 4 years 
and 6 months but no longer than 5 years and are willing to continue its use 
for con traception or contraception and heavy menstrual bleeding for up to 8 
years in total.
Study design Multi -center, open -label, uncontrolled study to be conducted in the US. 
Duration of the study treatment period is up to 3 years.
Methodology Monitoring of o ccurrence of pregnancies and evaluating the menstrual 
blood loss in the HMB subgroup
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 6of [ADDRESS_997271] to enter the treatment period
Prim ary variable Occurrence of pregnancies
Time point/fram e of 
measurement for prim ary 
variable(s)Treatment period of up to 3 years (total time of Mirena use up to 8 years). 
Plan for statistical analysis Analysis of primary variable: 
Primary Analysis: T he Pearl index (PI) will be calculated as the number of 
pregnancies w ithin years 6 -8 of Mirena use per 100 w omen years, and the 
corresponding 2 -sided 95% confidence interval will be provided. 
Secondary Analysis: The cumulative failure rate, i.e., the probability of 
getting pregnant will be calculated using the Kaplan Meier method in 
addition to the calculation of PIs .
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 7of 119
Table of contents
Cover page of the integrated protocol .....................................................................................1
1.Title page ............................................................................................................................2
Signature [CONTACT_8152]’s medically responsible person ......................................................[ADDRESS_997272] ...................................................................................35
9.2.2 Screening 
–Visit 1 ......................................................................................................35
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 8of 119
9.2.3 Baseline –Visit 2 ................................ ................................ ................................ ........36
9.2.4 6- month visit –Visit 3 ................................ ................................ ................................ .36
9.2.5 12- month visit –Visit 4 (End of Year 6 of Mirena use) ................................ .............37
9.2.6 18- month visit –Visit 5 ................................ ................................ ...............................37
9.2.7 24 –month visit –Visit 6 (End of Year 7 of Mirena use) ................................ ...........38
9.2.8 30- month visit –Visit 7 ................................ ................................ ...............................38
9.2.9 36- month visit, EOT –Visit 8 (End of Year 8 of Mirena use) ................................ ...39
9.2.10 3- week follow -up call (EOS) ................................ ................................ ......................[ADDRESS_997273] for return -to-fertility ......................................................40
9.3 Population characteristics ...............................................................................................40
9.3.1 Demographic ...............................................................................................................40
9.3.2 Medical history ............................................................................................................40
9.3.3 Reproductive and menstrual history ............................................................................40
9.3.4 Other baseline characteristics ......................................................................................40
[IP_ADDRESS] Indication for current Mirena ...................................................................................40
9.4 Efficacy ...........................................................................................................................41
9.4.1 Occurrence of pregnancies ..........................................................................................41
[IP_ADDRESS] Pregnancies during the study ...................................................................................41
[IP_ADDRESS] Pregnancies occurring after the end of study  treatment ...........................................41
9.4.2 Assessment of menstrual blood loss (MBL) b y alkali ne hematin method ..................
42
9.5 Pharmacokinetics / pharmacod ynamics .........................................................................42
9.5.1 Sample collection ........................................................................................................42
9.5.2 Drug measurements .....................................................................................................43
9.5.3 Pharmacokinetic evaluation ........................................................................................43
9.5.4 Residual L
NG content analy sis...................................................................................44
9.6 Safety ..............................................................................................................................44
9.6.1 Adverse events ............................................................................................................44
[IP_ADDRESS]
Definitions................................................................................................................44
[IP_ADDRESS] Classifications for adverse event assessment ...........................................................46
[IP_ADDRESS] Assessments and documentation of adverse events .................................................48
[IP_ADDRESS]
Reporting of serious adverse eve nts.........................................................................49
[IP_ADDRESS] Expected adverse events ..........................................................................................50
9.6.2 Pregnancies .................................................................................................................50
9.6.3 Further safet y
..............................................................................................................50
[IP_ADDRESS] Vital signs and weight ..............................................................................................50
[IP_ADDRESS] Physical examination ...............................................................................................50
[IP_ADDRESS] Gynecological examination .....................................................................................50
[IP_ADDRESS] Pregnancy  test................................ ................................ ................................ ..........51
[IP_ADDRESS] Cervical smear ................................ ................................ ................................ .........51
[IP_ADDRESS] Test for Chlamy dia................................ ................................ ................................ ..52
[IP_ADDRESS] Safety  laboratory  tests ................................ ................................ ..............................52
[IP_ADDRESS] Presence of Mirena removal threads ................................ ................................ ........53
[IP_ADDRESS] Expulsion of Mirena ................................ ................................ ................................53
[IP_ADDRESS] Perforation b y Mirena ................................ ................................ ..............................54
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 9of 119
[IP_ADDRESS] Pelvic inflammatory  disease ................................ ................................ ....................54
[IP_ADDRESS] Uterine bleeding .......................................................................................................54
9.7
Other procedures and variables ......................................................................................55
9.7.1 eDiary ..........................................................................................................................55
9.7.2 Continuing need of contraception ...............................................................................55
9.7.3 Mirena removal –assessment of the ease of the procedure (b y investigator) and 
pain during the rem oval (by  [CONTACT_1130]) ..........................................................................[ADDRESS_997274] satisfaction with Mirena .................................................................................56
9.7.5 Back -up contraception ................................................................................................56
9.8
Appropriateness of procedures / measurements .............................................................56
10.Statistical methods and determination of sample size ..................................................56
10.1 General considerations ...................................................................................................56
10.2 Analy sis sets ...................................................................................................................57
10.3 Variables and planned statistical anal yses......................................................................57
10.3.1 Variables .....................................................................................................................58
[IP_ADDRESS] Efficacy  variables
.....................................................................................................58
[IP_ADDRESS] Safety
 variables ........................................................................................................59
[IP_ADDRESS] Other variables .........................................................................................................59
10.3.2 Statistical methods ................................ ................................ ................................ ......60
[IP_ADDRESS] Analy sis of the primary  variable ..............................................................................60
[IP_ADDRESS] Analy sis of the secondary  variables .........................................................................62
[IP_ADDRESS] Analy sis of safet y variables .....................................................................................64
[IP_ADDRESS] Other variables .........................................................................................................[ADDRESS_997275] information and consent ................................ ................................ ....................74
13.5 Publication policy  and use of data ................................ ................................ ..................75
13.6 Compensation for health damage of subjects / insurance ..............................................[ADDRESS_997276] ....................................................................................................................76
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 10of 119
15.Protocol amendments ................................ ................................ ................................ ......78
15.1 Amendment 1 –dated 20 SEP 2017 ................................ ................................ ...............78
15.1.1 Overview of the changes to the study .........................................................................78
[IP_ADDRESS]
Modification 1: Addition of the 6- year analy sis and the required assessments 
needed for the anal yses at Year 6 ............................................................................78
[IP_ADDRESS] Modification 2: Guidance about number of 34 -or 35 -year old women to be 
included into the screening period ...........................................................................78
[IP_ADDRESS] Modification 3: I nformation on inclusion range for laboratory  values added .........
79
[IP_ADDRESS] Modification 4: Revision of the c riteria for mandatory  withdrawal from the 
study .........................................................................................................................79
[IP_ADDRESS]
Modification 5: Clarification on counting of pregnancies with the est imated date 
of conception within 7 days after the end of Mirena treatment for the Pearl 
Index calculation ......................................................................................................79
[IP_ADDRESS] Modificatio n 6: Clarification of the post -treatment pregnancy  tracking process 
(PTPT) ......................................................................................................................79
[IP_ADDRESS] Modification 7: Clarification and correction of terms used in the definitions for 
calculation of crude exposure time ..........................................................................80
[IP_ADDRESS]
Modification 8: Clarification of ex cluded exposure time due to back -up 
contraception use .....................................................................................................80
[IP_ADDRESS] Modification 9: Addition of sensitivity
 anal ysis for PI ...........................................80
[IP_ADDRESS] Modification 10: Addition of a reference to the statistical analy sis plan 
regarding handling of partial or missing data ................................ ..........................80
[IP_ADDRESS] Modification 11: Clarification of the definition of clinical change in bleeding 
profile regarding HMB and of the proportion of subjects with clinical change in 
bleeding profile regarding HMB..............................................................................80
[IP_ADDRESS] Modification 12: Change in exclusion c riterion about simultaneous participation 
in other trials ............................................................................................................81
[IP_ADDRESS] Modification 13: Withdrawal from stud y if heav y menstrual 
bleeding returns.......81
[IP_ADDRESS] Modification 14: Reference to a local laboratory  removed from the text. ...............81
[IP_ADDRESS] Modification 15: Revised terminology  of the adverse events to be included in 
the main safet y anal ysis, and correction of the list of other safet y variables. ..........81
[IP_ADDRESS] Modification 16: I mproved instructions for collection of used sanitary  products ...82
[IP_ADDRESS] Modification 17: Correction of the in cervical smear instructions at EOT visit ......82
[IP_ADDRESS] Modification 18: Change in the SOPs to be followed for assessing important 
deviations .................................................................................................................82
[IP_ADDRESS]
Modification 19: Definition of a bleeding/spotting epi[INVESTIGATOR_1865]....................................82
[IP_ADDRESS] Modification 20: Update of the background information ........................................82
[IP_ADDRESS] Modification 21: Information on post -study  contraception .....................................83
[IP_ADDRESS] Modification 22: Mandatory  TVUS if removal threads are not found
....................83
[IP_ADDRESS] Modification 23: Clarifications ................................................................................83
[IP_ADDRESS] Modification 24: I nstructions regarding bleeding irregularities detected in 
women using Mirena for contraception only ...........................................................83
[IP_ADDRESS] Modification 25: Collection of age at Baseline visit (Visit 2) ................................ .83
[IP_ADDRESS] Modification 26: Revision of the definition for start of treatment period for the 
primary  variable .......................................................................................................84
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 11of 119
15.1.2 Changes to the protocol text ................................ ................................ ........................84
[IP_ADDRESS] Section 2. Sy nopsis ..................................................................................................85
[IP_ADDRESS] Section 3. I
ntroduction .............................................................................................85
[IP_ADDRESS] Section 5 Study  design .............................................................................................86
[IP_ADDRESS] Section 6 Study  population ......................................................................................86
[IP_ADDRESS] Section 6.2 Exclusion criteria ..................................................................................87
[IP_ADDRESS] Section 6.4.1 Withdrawal .........................................................................................87
[IP_ADDRESS] Section 9.1 Tabular schedule of evaluations ............................................................89
[IP_ADDRESS]
Section 9.2 Visit description....................................................................................96
[IP_ADDRESS] Section 9.2.3 Baseline –Visit 2 ...............................................................................97
[IP_ADDRESS]
Section 9.2.5 12- month visit –Visit 4 (End of Year 6 of Mirena use) .................... 97
[IP_ADDRESS] Section 9.2.8 30- month visit –Visit 7 ................................ ................................ .....98
[IP_ADDRESS] Section 9.2.9 36- month visit, EOT –Visit 8 (End of Year 8 of Mirena use) ..........99
[IP_ADDRESS] Section 9.2.10 3- week follow -up call (EOS) ................................ .........................100
[IP_ADDRESS] Section 9.2.[ADDRESS_997277] -study  pregnancies ................. 100
[IP_ADDRESS] Section 9.2.[ADDRESS_997278] for return- to-fertility .......................101
[IP_ADDRESS] Section 9.3.1 Demographic....................................................................................101
[IP_ADDRESS] Section [IP_ADDRESS] Pregnancies during the stud y ................................ ........................102
[IP_ADDRESS] Section [IP_ADDRESS] Pregnancies occurring after the end of study  treatment ................ 102
[IP_ADDRESS] Section [IP_ADDRESS] Test for chlamy dia........................................................................103
[IP_ADDRESS] Section [IP_ADDRESS] Safety  laboratory  tests ...................................................................104
[IP_ADDRESS]
Section [IP_ADDRESS] Presence of Mirena removal threads.............................................104
[IP_ADDRESS]
Section [IP_ADDRESS] Uterine bleeding..........................................................................105
[IP_ADDRESS] Section 9.7.1 eDiary ...............................................................................................105
[IP_ADDRESS] Section 9.7.[ADDRESS_997279] satisfaction with Mirena ......................................................106
[IP_ADDRESS] Section 10.2 Analy sis sets ......................................................................................106
[IP_ADDRESS] Section 10.3 Variables and planned statistical analy ses........................................107
[IP_ADDRESS] Section [IP_ADDRESS].1 Primary efficacy  variable .........................................................108
[IP_ADDRESS]
Section [IP_ADDRESS] Safety  variables ................................ ................................ ...........109
[IP_ADDRESS] Section [IP_ADDRESS] Analy sis of the primary  variable .................................................110
[IP_ADDRESS]
Section [IP_ADDRESS].1 Menstrual blood loss................................................................113
[IP_ADDRESS]
Section [IP_ADDRESS].2 Categorized menstrual blood loss (MBL) (<80ml / 30 day s)..114
[IP_ADDRESS] Section [IP_ADDRESS] Analy sis of safet y variables ................................ ........................116
[IP_ADDRESS] Section [IP_ADDRESS].2 Bleeding pattern .......................................................................116
[IP_ADDRESS] Section 10.5 Planned interim analy ses...................................................................118
[IP_ADDRESS]
Section 11.1 Data recording...................................................................................118
[IP_ADDRESS] Section 13.1 I nvestigators and other study  personnel
............................................119
[IP_ADDRESS] Section [ADDRESS_997280] ................................ ................................ .......................119
Table of Tables
Table 3–1: Prediction of in vivo release rates based on residual content data from Report 
A15942 ................................ ................................ ................................ ..................16
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 12of 119
Table 3–2: Comparison of average LNG serum concentrations (% CV) data of Jay dess/Sky la, 
LCS16 and Mirena ................................................................................................17
Table 9
–1Schedule of activities and evaluations –amended ................................................29
Table 9
–2 Schedule of activities needed for the MBL evaluations – amended .....................33
Table 9–3 Uterine bleeding – bleeding intensity  definitions –amended ...............................55
Table 10
–1 Definition of crude exposure times – amended ....................................................60
Table 10
–2Bleeding Intensity  Codes and WHO Definitions for Bleeding Intensity  –amended
...............................................................................................................................65
Table 10
–3Example of an Assessment of Bleeding Epi[INVESTIGATOR_1841] ................................................66
Table of Figures
Figure 5 —1 Overview of the stud y design ................................ ................................ .......... 19
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 13of [ADDRESS_997281] research organization
CSR Clinical Study Report
CV Coefficient of variation
DNA Deoxyribonucleic acid
eCRF Electronic case report form
e.g. Exempli gratia (for example)
EMA European Medicines Agency
EOS End of study
EOT End of treatment
FAS Full analysis set
FDA Food and Drug Administration
FPFV First patient first visit
FSH Follicle -stimulating hormone
GCL Global Clinical Leader
GCP Good Clinical Practice
GLP Good Laboratory Practices
HbA1c Glyc osylated hemoglobin
hCG Human chorionic gonadotropin
HDL High density lipoprotein
HIV Human immunodeficiency virus
HMB Heavy menstrual bleeding
HPV Human papi[INVESTIGATOR_730075]’s Brochure
ICF Informed consent form
ICH International Council on Harmonization
i.e. Id est (that is)
IEC Independent Ethics Committee
IME Important Medical Event
IRB Institutional Review Board
IUD Intrauterine device
IUS Intrauterine system
LC-MS Liquid chromatography -mass spectrometry
LCS Levonorgestrel contraceptive intrauterine system
LDL Low density lipoprotein
LNG Levonorgestrel
LPLV Last patient last visit
mIU milli International Unit
MBL Menstrual blood loss
MCH Mean corpuscular hemoglobin
MCV Mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activities
MET Mirena Extended Trial
mg milligram
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 14of [ADDRESS_997282] identification (number)
SOC System  organ class
SOP Standard Operating Procedure
STD Sexually transmitted disease
STIs Sexually transmissible infections
S[LOCATION_003]Rs Suspected, unexpected, serious adverse reactions
TVUS Transvaginal ultrasound
US [LOCATION_002] of America
WHO World Health Organization 
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 15of 119
3. Introduction
Background
Mirena , a levonorgestrel -releasing intrauterine s ystem (LNG IUS; initial in vitro release rate 
20gLNG / day),hasbeen proven a safe and reliable method of contraception over the 
5years of labeled use.  It has been on the market since mid-1990s in most European countries 
and since 2001 in the U nited States (US) .
This section was changed in Amendment 1, see Section [IP_ADDRESS].
Thre e contraceptive efficacy  studies on extended use bey ond the indicated 5 years up to 7 
years (1,2,3) have been published. In a comparative study  the effectiveness of the 
contraceptive implant and the 52 -mg hormonal intrauterine device in women using the 
method for 2 years beyond the approved duration was evaluated ( 1). Among [ADDRESS_997283] been 
reported. The failure rate in the sixth y ear of use of the LNG IUS is calculated as 0.25 
(95% CI, 0.04- 1.42) per 100 woman -years; failure rate during the seventh year is 0.43 (95% 
CI 0.08- 2.39) per 100 woman -years. In the recently published stud y by [CONTACT_730105] 2016 (2), 
the overall pregnancy  rate of the TCu380A wa s significantly  higher than that of the LNG 
IUD:at the end of the seventh y ear the cumulative rate was 2.45 (standard error [SE] 0.44)
per 100 for the TCu380A and 0.5 3 (SE 0.21) per 100 for the LNG IUD. In the earlier study  
(3), no pregnancies occurred to users of either device in years 6 and 7. Cumulative pregnancy 
rates were 1.1 per 100 at seven years for the LNG IUS and 1.4 per 100 for the copper -
releasing IUDs .Hidalgo et al (2009) (4) evaluated the s
erum levonorgestrel levels and 
endometrial thickness during extended use of the levonorgestrel -releasing intrauterine s ystem
up to 8 1/[ADDRESS_997284] 2 months of use. Despi[INVESTIGATOR_730076], menstrual bleeding was reinstated in many  cases. The incidence of ame norrhea 
decreased from 41.8% at 84 months to 31.5% at 102 months of use (4).
The in vivo L NG r elease rate at the end of the 5 years of Mirena use is 10.1 µg/d which is 
higher than that for other L NG IUS, Jay dess (
5.4µg/d at 3 years) and LCS16 ( 7.4µg/d at 5 
years)(see Table 3–1), suggesting that the product would be efficacious in preventing 
pregnancy  for a longer period of use.  
This study  will evaluate the contraceptive eff icacy of Mirena during the extended use for up 
to [ADDRESS_997285] on heav y menstrual bleeding during the extended use 
will be studied in a subgroup of women for whom the Mirena was prescribed for heav y 
menstrual bleeding (as a seconda ry indication to contraception).
Further details can be found in the latest available version of the investigator's brochure, 
which contains comprehensive information on the study  drug.
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 16of 119
Rationale of the study
Mirena has a high contraceptive efficacy  resulting in a failure rate of approximately  0.2% at 
1year and a cumulative failure rate of approximately  0.7% at 5 y ears.  In addition, M irena
has been shown to reduce menstrual blood loss by [CONTACT_726] 90% after 1 year and to 
consequentl y increase blood hemoglobin level s (5).  Clinical practice has shown that M irena
often relieves dy smenorrhea and premenstrual s ymptoms.
  
Mirena is currently  indicated for use up to 5 y ears.  Bay er wishes to study  the extend ed
duration of use of Mirena up to 8 -years in the indication contraception .Depending on the 
results, this may  allow recommendation of a longer interval between the IUS pla cements in 
women who may  wish to continue use of Mirena for contraception bey ond 5 y ears.The 
planned study  will p rovide the basis for extension of Mirena use up to 8 years for 
contraception .
To support the extension of use over 8 years, a prediction of ty pi[INVESTIGATOR_730077] 5, 6, 7, and 8 years after insertion of the IUD was performed using population 
pharmacokinetic (PK) methods. The prediction was based on residual content data from 
Report A15942 and a first -order release was assu med.
Table 3–1: Prediction of in vivo release rates based on residual content data from 
Report A15942
Time point 
after 
insertionMirena
Residual LNG 
(mg)Mirena
Residual LNG 
(%)Mirena
in vivo release 
rate [µg/d]Jaydess/Skyla
in vivo release 
rate [µg/d]LCS16
in vivo release 
rate [µg/d]
3 years -- -- 13.7 5.4 8.0
5 years 24.2 46.5% 10.1 -- 7.4
6 years 20.7 39.9% 8.6 -- --
7 years 17.8 34.2% 7.4 -- --
8 years 15.3 29.3% 6.4 -- --
Table 3–1 shows the residual L NG content in the device after 5, 6, 7, and 8 years of use as 
amount in mg and in % of initial content (52 mg). Even after 8 years, about 30% of the initial 
content isstill in the L NG IUS. The t ypi[INVESTIGATOR_730078] 10 µg/d to 6.4 µg/d after 8 years of use. Compared to Jay dess/Sky la, which is the 
LNG IUS with the lowest release rate on the market, the a nticipated in vivo release rate for 
Mirena is still higher.
In support of the extended use of Mirena bey ond 5 y ears, serum LNG concentrations (5 years 
and bey ond, from Mirena in comparison with LCS16and Jaydess/ Skyla) are presented in 
Table 3–2 below:
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 17of 119
Table 3–2: Comparison of averag e LNG serum concentrations (% CV ) data of 
Jaydess/Skyla, LCS16 and Mirena
Time Jaydess/Skyla
(ng/L)LCS16
(ng/L)Mirena
(ng/L)
3years 68.5 (33.0%)a85.2 (63.9%)a165 (40.5%)a
5years - 64.0 (23.0%)e150 (35.6%)b
6.5years - - 76.3 (31.8%)c
8years - - 117 (50.4%)d
Abbreviations: CV=coefficient of variation; LNG=levonorgestrel
aA46796 CSR (6)
bB078 CSR (7)
cB073 CSR (8)
dSeeber B, et al. 2012 (13)
ePH-[ZIP_CODE] CSR (9)
The above data indicate that serum concentrations of LNG after 8 years of Mirena use are in 
a similar range compared to Jay dess/Sky la after 3 y ears of use as can be expected based on 
the similar in vivo release rates. 
The simulated in vivo release rates for Mirena support the extended use up to 8 y ears.
Benefit -risk assessment
Benefit /risk balance for Mirena in Contraception :
Mirena has a very  high contraceptive efficacy  which is less dependent on user -compliance 
and compares favorabl y to other contraceptive methods including barrier methods, combined 
oral contraceptive , progestin -only pi[INVESTIGATOR_4382], injectables, and copper IUDs (eg. Pa raG ard). Its 
efficacy  is not influenced by  [CONTACT_730106]-inducing drugs (in contrast to other hormonal 
methods). Further non -contraceptive benefits include decreased menstrual blood loss and 
alleviation of dy smenorrhea. Some studies have also suggested that Mirena may  have 
beneficial effects on pelvic pain related to endometriosis or adenomy osis. Due to its mainly  
local mechanism of action and the fact that it does not contain estrogens, Mirena is suitable 
for man y women in whom combined contraceptive meth ods are contraindicated or not 
desirable. Mirena can be inserted immediately  after a first trimester abortion, with immediate 
effect of contraceptive efficacy . Mirena does not interfere with lactation.
The majority  of Mirena users experience bleeding chang es. Other "very  common" adverse 
drug reactions ( ADRs ) in clinical trials include headache and abdominal/pelvic pain. Ovarian 
cysts are observed under Mirena use but are in the vast majority , transient and asy mptomatic. 
Hormonal side effects of levonorgestr el are less frequently  observed.
Identified safet y risks are device related complications (such as expulsions), and side effects 
caused b y levonorgestrel. Important safet y risks/serious events are rare ( pelvic inflammatory  
disease [PID], uterine perforation) and can be managed with adequate medical or surgical 
treatment. Clinical trials and observational studies have established that the risk of PI D 
associated with insertion of intrauterine contraceptives is confined to the first weeks after 
insertion. A la rge European active surveillance study  (EURAS -IUD) (10)showed that the 
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 18of [ADDRESS_997286] associated with the insertion of an intrauterine 
contraceptive may  ultimately  lead to increased use of a highl y effective method of 
contraception. 
Contraceptive efficacy  during extended duration of use of Mirena during y ears 6, 7 and 8 is 
expected to be high, as the lower release rate of other LNG IUS products (Sky la and LCS16) 
have been proven to provide h igh efficacy  with a Pearl Index of less than 0.5 up to 3 y ears
(11)and 5 years(9) . Risks associated with contraceptive failure (i.e. risk of ectopic 
pregnancy , and risk to a pregnancy  with Mirena in situ) are not expected to change during 
years 6, 7 and 8 with continued high contraceptive efficacy , which will be demonstrated in 
the proposed clinical study .
The bleeding profile during the extended use of the same device is expected to remain 
favorable and similar to that observed during the use up to 5 years. The incidence of 
infrequent bleeding or absence of bleeding increase with time in users of LNG IUS, while the 
incidence of prolonged and frequent bleeding decreases. Absence of bleeding is associated 
with high overall satisfaction and continuation rates in women using a second consecutive 
Mirena (12).
The study  will also analyze the removal procedure after [ADDRESS_997287] for the extended duration of use. No new risks are anticipated.
In summary , a positive benefit risk balance is anticipated during 
the exten ded use of Mirena 
for contraception up to 8 y ears.
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 19of 119
4. Study objectives
Primary  objective of the study  is to assess the contraceptive efficacy of Mirena beyond 5 
years up to 8 y ears of use.
Secon dary objectives for the study  are the assessment of menstrual blood loss ( in women that 
had Mirena inserted for the indication heav y menstrual bleeding [ HMB ]) and safet y.
Further objective s are the population pharmacokinetic evaluation of LNG plasma 
concentration data and evaluation of user satisfaction .
5. Study design
Design overview
This is a multi -center, uncontrolled, single group study to be conducted in the US only.  
Study  design is presented be low in 
Figure 5—1.
Figure 5
—1 Overview of the study design
Thetarget for the total number of women to be included in the extended treatment period is
360women (200 women to complete study  treatment ). To evaluate the effect of extended 
Mirena use on HMB, 
it is targeted that 10% of the women to be treated ( i.e. 36 women out of 
360) should have Mirena prescrib ed for the treatment of HMB in addition to contraception.   
Please note, subjects who have Mirena prescribed for contraception and heavy  menstrual 
bleeding will have to consent to the HMB subgroup procedures. 

Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 20of [ADDRESS_997288] for 4 years and 6 months.  Screening 
activities should be completed within 60 day s after signed informed consent to allow enough 
time for the evaluation of the subjects’ eligibility  to the study .  Baseline visit (Visit 2) will be 
scheduled to take place 0 to 14 day s before the end of Year 5 of Mirena use ; and this is the 
start of the treatment period . Treatment period is defined as the 3 -year period following the 
Baseline visit , i.e. years 6, 7 and 8 of extended use of Mirena. 
This section was 
changed in Amendment 1, see Section [IP_ADDRESS]. An anal ysis of the efficacy  
and safet y data will be 
conducted after all subjects have either completed 6 years of treatment
(i.e. completed 1 year in the study ), or prematurely  terminated th eir stud y participation before 
this time point. Another anal ysis of the efficacy  and safety data will be conducted after all 
subjects have either completed 7 y ears of treatment (i.e. completed 2 years in the study ), or 
prematurel y terminated their study  participation before this time point.
Final anal ysis will be done after all subjects have either completed [ADDRESS_997289] -
treatment pregnancies will be 3 months after the end of the treatment for subjects who
prematurel y discontinued study  treatment. They  will be contact[CONTACT_730107] “pregnancy ”, “death”, or “withdrawal b y subject” where the subject has 
withdrawn main consent during stud y conduct and wishes to stop future contact [CONTACT_36362] . 
For subjects that had withdrawn consent during s tudy, but consented to post study  
participation follow -up, post treatment pregnancy tracking information is expected.
Follow -up period for the tracking of post- treatment pregnancies will be up to 12 months for 
subjects who discontinue Mirena use because of a wish for pregnancy  (i.e. collection of 
return -to-fertility  data). Subjects who discontinue treatment because of a wish for pregnancy  
will receive a second telephone call at [ADDRESS_997290] and had not reported a pregnancy  at the time 
of the 3
-month follow -up call.
Levels of LNG (plasma) and sex hormone binding globulin (SHBG) (serum) will be 
monitored by  [CONTACT_730108] ,and will be evaluated using a population PK 
approach. In addition, serum L NG and SHBG levels will also be determined at the Mirena
removal in all subjects discontinuing the stud y prematurely. Similarl y, residual L NG content 
will be determined after remova l at the end of the study  for all subjects who had entered the 
treatment period whether they  completed the study  ordiscontin uedprematurely .  The
concentration values for LNG and SHBG 
and residual L NG content data will be entered into 
the database at pre -planned database opening.  The results on population pharmacokinetics 
will be reported separately .
Primary varia
ble
Primary  efficacy  variable is the occurrence of pregnancy .
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 21of 119
Justification of the design
The efficacy  and safet y of Mirena for contraception and HMB has been proven in a large 
clinical development program for up to 5 years, while no compan y sponsored study data is 
currentl y available for use of Mirena beyond 5 years. New clinical data is therefore needed. 
The planned stud y will assess the contr aceptive efficacy  of Mirena during extended use 
beyond 5 y ears up to 8 years. In addition, approximately  10% of the total number of women 
in the study  will have had Mirena prescribed for contraception and heav y menstrual bleeding; 
these subjects will form the HMB subgroup to show that the efficacy  in terms of menstrual 
blood loss is maintained during extended use. This study  design allows access for extended 
use of Mirena in women who have alread y been using Mirena close to the end of the 
currentl y approved maximum period of use and therefore an option for longer interval 
between the IUS placements in those women, who wish to continue use of Mirena for 
contraception or contraception and heav y menstrual bleeding (HMB) beyond [ADDRESS_997291] (i.e. 
end of study  phone call at 3 weeks after Mirena removal) has been reached in all centers.
Primary completion
The primary  completion event for this study  is the last patient last visit (L PLV) .
The primary  completion date for this study  according to the FDA Amendment Act is 
specified in a separate document (not part of this study  protocol).
6. Study population
This section was changed in Amendment 1, see Sections [IP_ADDRESS], [IP_ADDRESS], and [IP_ADDRESS].
The study  will include fertile age women (18 to 35 y ears at the time of the screening visit ) 
currentl y using a Mirena for contraception or for contraception and heav y menstrual bleeding 
and who have had the Mirena in situ for at least 4 y ears and 6 months but no longer than 5 
years and are willing to continue its use for contraception or contraception and heav y 
menstrual bleeding for up to 8 y earsintotal. About 90% of the women included will be 18 to 
32 (inclusive) years of age at 
screening (visit 1)1.  In addition, t he aim is thatapproximately  
10% of the 
total number of women in the study  will have had Mirena prescribed for 
contracepti on and heav y menstrual bleeding ; these subjects will form the HMB subgroup . 
Subjects who have Mirena prescribed for contraception and heav y menstrual bleeding will 
have to consent to the HMB subgroup procedures. The subjects must have a continuing need 
forcontraception during the entire duration of the study  (i.e. they  are sexually  active and at 
risk of pregnancy  during thestudy treatment period of [ADDRESS_997292] 
completed the baseline visit, for details see Section 10.4.
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 22of 119
with the current Mirena ). Women who have contraindications to use Mir ena according to the 
current US label will be excluded from participation in the study .
Women in need of contraception meeting all inclusion and presenting none of the exclusion 
criteria will be eligible for enrollment to the treatment phase in the study . Inclusion and 
exclusion criteria are checked at the screening visit. A re -check on eligibility  is to be done at 
baseline visit.
6.1 Inclusion criteria
1.Signed and dated informed consent
2.Women, 18 to 35 y ears of age at the time of screening (visit 1) who are cur rently  
using M irena for contraception or for contraception and heav y menstrual bleeding. 
The duration of use of the current M irena has to be at least 4 y ears 6 months at the 
start of screening phase but not more than 5 y ears at visit 2 and the woman 
is wi lling 
to continue with its use and has a continuing need for contraception .
3.Normal or clinicall y insignificant cervical smear not requiring further follow up (a 
cervical smear has to be taken at screening visit or a normal result has to be 
documented withi n the previous 6 months). Human papi[INVESTIGATOR_27509] (HPV) testing in 
subjects with aty pi[INVESTIGATOR_145582] (ASCUS) can be 
used as an adjunctive test. Subjects with ASCUS can be included provided they are 
negative for high -risk HPV strains.
6.2 Exclusion criteria
This section 
was changed in Amendment 1, see Section s [IP_ADDRESS] and [IP_ADDRESS].
1.Menopausal s ymptoms with FSH >30 mIU/ml
2.Pregnancy  or suspi[INVESTIGATOR_730079]
3.Uterine bleeding of unknown etiology
4.Untreated acute cervicitis or vaginitis or other lower genital tract infections (until 
successfull y treated)
5.Increased susceptibility  to pelvic infection
6.Acute pelvic inflammatory  disease (PID) or a 
history  of PID unless successfully  
treated and which , in the investigator’s opi[INVESTIGATOR_1649], has not negatively  affected subject’s
fertility  
7.Congenital or acquired uterine anomal y if it distorts the uterine cavity
8.Known or suspected breast cancer or other progestin
-sensitiv e cancer
9.History  of, diagnosed or suspected genital or other malignancy  (excluding treated 
squamous cell carcinoma of the skin), and untreated cervical dy splasia
10. Known or suspected uterine or cervical neoplasia
11.Any active acute liver disease or liver tumor (benign or malignant)
12.Clinically  significant endometrial poly p(s), which, in the opi[INVESTIGATOR_871], 
will interfere with the assessment of the bleeding profile during the stud y.
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 23of [ADDRESS_997293](s).
14. Concomitant use of other sex- hormone containing preparations
15.Hypersensitivity  to an y component of Mirena
16.Any diseases or conditions that can compromise the function of the body  systems and 
could result in altered absorption, excessive accumulation, impaired metabolism, or 
altered exc retion of the study  medication
17.Any diseases or conditions that might interfere with the conduct of the study  or the 
interpretation of the results
18. Abuse of alcohol, drugs, or medicine (e.g., laxatives)
19.Inability  to cooperate with the study  procedures for an y reason, including the 
following examples: language comprehension, ps ychiatric illness, inability  to get to 
the study  site
20. Known or suspected HIV infection or high risk for STD. Conditions associated with 
increased susceptibility  to infection with microor ganisms, including such conditions 
as leukemia, human immunodeficiency  virus (HIV) -positive status, acquired immune 
deficiency  syndrome (AIDS).
21.Laboratory  values outside inclusion range before baseline and considered clinically  
releva nt (see Section [IP_ADDRESS] ) .
22.Simultaneous participation in another clinical study  with investigational medicinal 
product(s). Participation in another clinical trial prior to study  entry  that might have 
an impact on the study  objectives, at the discretion of the investigator.
23.Close affiliation with the investigational site; e.g. a close relative of the investigator, 
dependent person (e.g. employ ee or student of investigational site, or sponsor’s staff)
24.Previous enrollment to the study  (i.e. re -screening allowed only  as described in 
section 6.4.1)
6.3 Justification of selection criteria
The entry  criteria defined for the study  ensure selection of fertile women who are willing to 
continue with M
irena as their method of contraception.   Entry  criteria are chosen to ensure 
that subjects with specific risks related to the use of the study  drug and/or subjects with 
conditions which may  have an effect on the study  endpoints are excluded.
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 24of 119
6.4 Withdraw al of subjects from study
6.4.1 Withdrawal
Withdrawal criteria
This section was changed in Amendment 1, see Section [IP_ADDRESS] and [IP_ADDRESS].
Subjects 
must be withdrawn from the stud y if an y of the following occurs:
At their own request. At any  time during the study and without giving reasons, a 
subject may  decline to participate further.  The subject will not suffer an y 
disadvantage as a result.
Complete or partial expulsion of the Mirena
Removal of Mirena outside the study  procedures
Pregnancy
Partial or total perforation of the uterus or cervix by  [CONTACT_730109]
Acute pelvic inflammatory  disease (PID) not responding to treatment
Genital malignancy (e.g., uterine o
r cervical malignancy )
Severe arterial disease such as stroke or m yocardial infarction (MI)
Liver tumor (benign or malignant)
Allergic reaction to the study  medication or an y of its components
If, in the investigator’s opi[INVESTIGATOR_1649], continuation of the study  would be harmful to the 
subject’s well -being
Should the subject, during the course of the study , develop conditions which would 
have prevented her entry  into the study  according to the exclusion criteria, she must 
be withdrawn immediately if safet y is concer ned. In other cases, the investigator will 
decide if there is a conflict with study  objectives.
Participation in any  other clinical study  during the duration of this study
Subjects may be withdrawn from the stud y if an y of the following occurs:
Coagulopat hy or use of anticoagulant
Migraine, focal migraine with asy mmetrical visual loss or other sy mptoms indicating 
transient cerebral ischemia
Exceptionally  severe headache
Marked increase of blood pressure
Jaundice
Non-attendance of visits despi[INVESTIGATOR_730080] (i.e. if a subject does 
not attend consecutive visits without a major reason) .
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 25of [ADDRESS_997294] appropriate means for excluding that a pregnancy  has 
occurred (e.g. home pregnancy test kit, menstrual history , etc).  All methods 
and results regarding determination of pregnancy  must be documented.
Serious adverse event, adverse event, laboratory  abnormality  of considerable clinical 
concern or considerabl e worsening of the subjec t's clinical symptoms
At the specific request of the sponsor and in liaison with the investigator (e.g. obvious 
non-compliance, safet y concerns).
Return of heav y menstrual bleeding , if it affects the subject’s well-being, based on the 
investigator’s clinical ju dgment
The reasons for an y withdrawal are to be fully  documented on the eCRF.
End of treatment visit (Visit 
8)and the end of study phone call (3 weeks after the Mirena 
removal) must be performed also for all subjects discontinuing the study  prematurel y. 
Depending on the time point of withdrawal, a withdrawn subject is referred to as either 
“screening failure” or “dropout” as specified below:
Screening failure
A subject who, for an y reason (e.g. failure to satisfy the entry  criteria), terminates the study  
before the time point used for the definition of “dropout” ( i.e. before com pletion of the 
baseline visit, V isit 2 ) is regarded a “screening failure”.  
Re-starting the defined set of screening procedures to enable the “screening failure” subject’s 
particip
ation at a later time point is not allowed –with the following exceptions:
Initial screening occurred too earl y, i.e. before 4 years and 6 months of the Mirena use
The in- / exclusion criteria preventing the subject’s initial attempt to participate have 
been changed (via protocol amendment).
In an y case, the investigator has to ensure that the repeated screening procedures do not 
expose the subject to an unjustifiable health risk.  Also, for re -screening, the subject has to re-
sign the informed consent form, even if it was not changed after the subject’s previous 
screening.
Dropout
A subject who discontinues study  participation prematurely  for any  reason is defined as a 
“dropout” if the subject has alread y been deemed eligible to participate and completed t he
baseline visit (visit 2) .
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 26of [ADDRESS_997295]'s 
medical records. 
The subject may  object to the generation and processing of post -withdrawal data as specified 
in Section 13.4.
Any subject removed from the trial will remain under medical supervision until discharge or 
transfer is medically  acceptable.
Details 
for the premature termination of the study  as a whole (or components thereof) are 
provided in Section 12.
6.4.[ADDRESS_997296] completed the baseline visit (visit 2) andthereafter 
terminate their study  
participation prematurel ywill not be replaced.
6.[ADDRESS_997297] identification (SI D) number is a 9 -digit number consisting of:
Digits 1 to 5 = Unique center number
Digits 6 t o 9 = Current subject number within the center
Once allocated, the SID number will identify  the subject throughout the study .
If subject is re -screened, she will receive a new SID.
7. Treatments
7.1 Treatments to be administered
No study  drug (Mirena) will be pro vided by  [CONTACT_456].  Subjects enter this study  treatment 
period 
wearing a Mirena that was inserted 5 years earlier and will continue its use for an 
additional 3 y ears, i.e. up to a total of 8 y ears.  Subjects are required to provide 
documentation about t he prescription for the Mirena (including indication) and the date of 
insertion.
Test drug isMirena , anLNG intrauterine delivery  system (IUS) with an initial in vitro release 
rate of 20 µg LNG per day, used continuously . The total L NG content in Mirena is 52mg.
7.2
Identity of study treatment
See Section 7.1.
7.3 Treatment assignment
Not applicable, this is a 
single group stud y. A subjec t enter sthe study  with a Mirena in the 
uterus .
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 27of [ADDRESS_997298] for up to a total of 8 y ears.
7.4.1 Removal of Mirena
Timing of removal
Mirena should not remain in the uterus after 8years.
If pregnancy  is not desired, the removal should be carried out during menstruation, 
provided the woman is still experiencing regular menses. If removal will occur at 
other times during the cycle, start a new contraceptive method a week prior to 
removal. If removal occurs at other times during the cy cle and the woman has had 
intercourse in the week prior to removal, she is at ris k of pregnancy .See also section 
8.2.
7.[ADDRESS_997299] be properl y documented according to t
he sponsor’s agreed and 
specified procedures. Written instructions will be made available to all affected parties.
Return of the Mirenas to the sponsor’s representative
If a subject discontinues her study participation prematurel yor completes the 8 years of use , 
the Mirena should be removed by  [CONTACT_730110](s) with forceps.
After removal (or if the subject returns an expelled Mirena to the study site) the Mirena is to 
be rinsed in cold water, dried carefull y with a clean paper towel and packaged in a plastic 
pouch provided b y the sponsor; the pouch label needs to be completed . 
The used Mirena should be stored according to the pouch label text, in the provided pouches 
in locked storage facilities until returned to sponsor’ s representative.
If performing drug accountability  implies a potential risk of contamination, a safet y process/ 
guidance for handling returned drug will be provided.
In the event of Product Technical Complaint (e.g. technical difficulties with the IUS during 
removal ,pregnancy , expulsion), the respective forms need to be completed and returned with 
the Mirena in question to sponsor´s representative for further investigation according to 
sponsor´s instructions.
7.7 Treatment compliance
Please refer to section [IP_ADDRESS].
Integrated Clinical Study Protocol
No.  BAY 86-5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 28of [ADDRESS_997300] udy therapy
8.1 Concomitant therapy
For the use of concomitant medications please refer to Section 6.2(Exclusion criterion # 14). 
All medications taken during the stud y (i.e. starting with 
the date of informed consent) will 
be recorded in the eCRF using the trade name, indication, dose, unit, frequency , route of 
administration and dates of intake (i.e. start and stop dates).
8.[ADDRESS_997301] about the contraceptive options available after the 
study  treatment (at Visit 7, or before end of the study ).
If pregnancy  is not desired and if a woman wishes to continue using Mirena, a new s ystem 
can be inserte d immediately  after removal an y time during the cy cle.
If a subjec t with regular cy cles wants to start a different birth control method, time removal 
and initiation of new method to ensure continuous contraception. Either remove Mirena 
during the first [ADDRESS_997302] of practice, wi thout the 
sponsor’s involvement.
9. Procedures and variables
9.1 Tabular schedule of evaluations
This section 
was changed in Amendment 1, see Sections [IP_ADDRESS], [IP_ADDRESS] , [IP_ADDRESS] and 
[IP_ADDRESS].
Table 
9–1presents the schedule of activities and evaluations for the study .  The additional 
activities for the subjects in the HMB subgroup are display ed in Table 9–2.
Integrated Clinical Study Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 29of 119
Table 9–1 Schedule of activities and evaluations –amended
PeriodScreening
(0 to 6 mo)Treatment Period 
(3 years; Mirena y ears 6 thru 8)Pregnancy  Follow -up 
(up to 12 mo)
Visit
Prescreening 
contact 
(optional)
Screening 
BaselineEOTaEOS
All 
subjects3-mo 
contact
b12-mo 
contact
c
Visit number / 1 2 3 4 5 6 7 8   
Timingwithin 
60 day sDay 1 6 mo
±14 d12 mo
±14 d18 mo
±14 d24 mo
±14 d30 mo
±14 d36 mo
-14 d3 wks 
after 
EOT
-3 d3 mo 
after 
EOT
-7 d/+14 
d12 mo 
after 
EOT
+7 d
Duration of Mirena use4y 6 mo 
to 5 
years5 yearsd 6 years 7 years 8 years
Informative discussion about the study/ 
Distribution of subject informationX X
Informed consent X
Indication for Mirena and date of insertion X
In-/exclusion criteria X X
Demography X
Age at baseline X
Substance use -Tobacco X
Alcohol consumption X
Reproductive and menstrual history X
Medical history X
Physical examination X X X X
Vital signs, body weight X+height X X X
Gynecological exam. incl. breast palpation X X X X
Checking of Mirena threads X X X X X X X X
Cervical smeareX X
Chlamydia testfX
Integrated Clinical Study Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 30of 119
Table 9–1 Schedule of activities and evaluations –amended
PeriodScreening
(0 to 6 mo)Treatment Period 
(3 years; Mirena y ears 6 thru 8)Pregnancy  Follow -up 
(up to 12 mo)
Visit
Prescreening 
contact 
(optional)
Screening 
BaselineEOTaEOS
All 
subjects3-mo 
contact
b12-mo 
contact
c
Visit number / 1 2 3 4 5 6 7 8   
Timingwithin 
60 day sDay 1 6 mo
±14 d12 mo
±14 d18 mo
±14 d24 mo
±14 d30 mo
±14 d36 mo
-14 d3 wks 
after 
EOT
-3 d3 mo 
after 
EOT
-7 d/+14 
d12 mo 
after 
EOT
+[ADDRESS_997303] kits X X X X X X X
eDiary dispensed / collected X X
Back -up contraception (if used; eDiary)       
Record uterine bleeding ( daily, eDiary)       
Review of bleeding diary with subject X X X X X X
Subject s atisfaction with Mirena X X X X
Mirena removal X
Mirena removal: ease and pain 
assessmentX
Integrated Clinical Study Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 31of 119
Table 9–1 Schedule of activities and evaluations –amended
PeriodScreening
(0 to 6 mo)Treatment Period 
(3 years; Mirena y ears 6 thru 8)Pregnancy  Follow -up 
(up to 12 mo)
Visit
Prescreening 
contact 
(optional)
Screening 
BaselineEOTaEOS
All 
subjects3-mo 
contact
b12-mo 
contact
c
Visit number / 1 2 3 4 5 6 7 8   
Timingwithin 
60 day sDay 1 6 mo
±14 d12 mo
±14 d18 mo
±14 d24 mo
±14 d30 mo
±14 d36 mo
-14 d3 wks 
after 
EOT
-3 d3 mo 
after 
EOT
-7 d/+14 
d12 mo 
after 
EOT
+7 d
Duration of Mirena use4y 6 mo 
to 5 
years5 yearsd 6 years 7 years 8 years
Documenta tion of pregnancy/return to 
fertilityX X X
Please see next page for footnotes
Integrated Clinical Study Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 32of 119
Footnote Explanations :
a An End -of-Treatment Visit must be performed also for all subjects who discontinue treatment.  If a subject prematurely discontinues treatment, all efforts 
should be made to perform all the assessments scheduled for this EOT visit (Visit 8) including the EOS phone contact [ADDRESS_997304] is withdrawn from the study.
bFor s ubjects who prematurely discontinued study treatment unless the reason for discontinuation is “pregnancy”, “death”, or “withdrawal by [CONTACT_1130]” where 
the subject has withdrawn main consent during study conduct and wishes to stop future contact [CONTACT_36362]. Subjec ts that had withdrawn consent during 
study, but consented to post study participation follow -upwill be contact[CONTACT_730111]. See also Section 9.4.1 .
c Subjects t hat prematurely discontinued treatment due to ‘W ish for pregnancy’ will be contact[INVESTIGATOR_530]. If a subject was not pregnant at [ADDRESS_997305] was “Lost to Follow -up” at [ADDRESS_997306] is 
required . See also Section 9.4.1 .
d The baseline visit (Visit 2) should take place [ADDRESS_997307].
h PK sampling: All subjects: one sample to be taken at baseline and at EOT (or if subject prematurely discontinues prior to rem oval) per subject; and two 
randomized samples to be taken at two of the visits 3 – 6.
i PK sampling for subjects randomized to this visit.
d=day, EOS=end of study, EOT=end of treatment, m o=month, PK=phar macokinetics, wks=weeks, y=year
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 33of 119
Subjects in the HMB subgroup (i.e. all women who had the Mirena inserted for contraception 
and heav y menstrual bleeding) will collect their used sanitary products (provided by [CONTACT_3211]) 
during 4 periods of 30 days as shown in Table 9–2.  All used sanitary  products have to be 
returned to the stud y site as instructed in Section 9.4.2 and d isplay edin Table 9–2.
For subjects who have the Mirena inserted for contraception onl y: if bleeding irregularities 
develop during prolonged treatment, appropriate diagnostic measures should be taken by  [CONTACT_730112] .
Table 9
–2 Schedule of activities needed for the MBL evaluations –amended
HMB subgroup only –additiona l activities for baseline (BL) visit and treatment period . For all other 
activities and evaluations, see Table 9–1.
Period
ScreeningTreatment Period (Mirena y ears 6 thru 8)
Collection 
time30 day s after 
baseline 
visit,
Study  Days 
2 to 31 
(inclusive)Study  Days 
322 to 351 
(inclusive)
before Visit 4Study  Days 
687 to 716 
(inclusive)
before Visit 6Study  Days 
1052 to 1081 
(inclusive)
before EOT 
visit
Visit / visit 
number
Baseline (BL)
Visit 2
Return
Return
Visit 3
Return 
Visit 4
Visit 5
Return
Visit 6
Visit 7
Return
EOT
Visit 8
Dispense 
alkaline 
hematin kit X X X X
Collection of 
used sanitary 
products       
Return of 
used sanitary 
productsaX X X X X X X X
Study Day 1 = Day of the baseline visit (Visit 2)
a Used sanitary products should not be kept at home longer than [ADDRESS_997308] been used in the time periods indicated.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 34of 119
9.2 Visit description
General information
Timing of the visits
If not stated otherwise, the measures listed in the following sections will be performed b y or 
under the supervision of a study  site investigator.
There will be 8 scheduled study  visits: screening visit (Visit 1), baseline visit (Visit 2), 5 visits 
during the treatment phase (Visit 3 to 7) and the end-of- treatment visit (EOT, Visit 8) .  The 
end-of-study  visit (EOS) is a phone contact [INVESTIGATOR_136] 3 weeks after the EOT (all subjects) .  
In addition, there will be up to [ADDRESS_997309] is for subjects who prematurely  discontinued study  treatment 
unless the reason for discontinuation is “pregnancy”, “death”, or “withdrawal by  [CONTACT_1130]” 
where th e subject has withdrawn main consent during study  conduct and wishes to stop future 
contact [CONTACT_36362] . For subjects that had withdrawn consent during study , but consented to 
post study  participation follow -
up, will be contact[INVESTIGATOR_530].  If subjects could not be contact[CONTACT_6811] 3 
months, they  will be considered “Lost to Follow - up”for post -study  pregnancy  tracking .  
12-month contact [CONTACT_730113] ‘Wish for 
pregnancy ’
.If a subject was not pregnant at 3- month contact [CONTACT_730114], a [ADDRESS_997310] was “Lost to Follow -up” at [ADDRESS_997311] is required .  For details, see Section [IP_ADDRESS].
The screening period can start when the subject has had the Mirena in place for 4 y ears and 
6months.  Screening period is up to 6 months
.  Screening activities should be completed 
within 60 days after signing the informed consent. The baseline visit (Visit 2) should take 
place 14 to 0 day s before the end of Year 5 of Mirena use.
The timing of the visits is based on the date of the baseline visit .  Treatment period starts at 
the baseline vis it (Visit 2, defined as Study Day 1).
The foll owing visit windows are allowed
:
Visits 3 to 7 (during treatment) should be performed ±2 weeks of the scheduled day .
Visit 8 (EOT) should be performed at the earliest 2 weeks before the scheduled day  
and not later.
Follow -up contact (EOS) should take place 3 weeks after the EOT (- [ADDRESS_997312], the investigator, at his/her discretion, may  
arrange visits in addition to the scheduled study  visits.  Possible reasons for unscheduled 
visits include suspi[INVESTIGATOR_730081] a safety  concern.
Informed consent
Before any screening examination takes place, potentially  eligible subjects will be given a full 
explanation about what the participation in the study  would involve. This will be done both 
verball y and in writing by [CONTACT_730115] i nformed consent 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 35of 119
form by  [CONTACT_599673]. Subjects will be given sufficient time to consider their 
participation in the study  and to ask any  questions about the study . Subjects willing to take 
part in the study  will then be asked to sign and date t he informed consent form (see Section 
13.4). 
Screening examinations will only  be performed after the site staff has received the subject’s 
signed and dated informe d consent form .
9.2.[ADDRESS_997313]
Before the screening visit (Visit 1), an optional pre-screening contact [CONTACT_730116][INVESTIGATOR_1306] y occur via telephone or as a response to an advertisement. During this contact, the 
study  candidate may be interviewed for suitability to participate in the study  consistent with 
the entry  criteria of the study . The pre -screening contact [CONTACT_730117], stud y nurse, or other member of the study staff specifically trained for this task.
After the pre -screening telephone discussion, the subject information form and the informed 
consent form may  be sent to the subject for further information. Regardless of whether the 
subject information form is sent to the subject, the details of the stud y must be thoroughly  
discussed and reviewed with the subject at the screening visit (Visit 1) before obtaining the 
signed informed consent form.
9.2.2 Screening – Visit 1
At the Screening Visit (Visit 1), the following procedures and assessments will be done:
Informative discussion about the study ; distribut ion of subject information form .  
Note: This must occur at the Screening Visit even if the subject information form
was sent to the subject following a pre -screening contact.
Obtain signed and dated ICF (Sect ion13.4); allocate the unique SID number (Section 
6.5)
Record the prescribed indication for Mirena and the date of Mirena insertion
(documentation required, see also Section 7.1)
Check of inclusion/exclusion criteria (Sections 6.1 and6.2)
Interview for the following:
Demographics, alcohol consumption, and smoking habits (Section 9.3.1)
Medical history  (Section 9.3.2)
Reproductive and menstrual history  (Section 9.3.3 )
Concomitant medications (Section 8.1)
AEs (Section 9.6.1.  The recording period of AEs begins at the sig ning of 
the ICF)
Perform urine pregnancy test (Section [IP_ADDRESS])
Assess vital signs and weight (including height ; Section [IP_ADDRESS])
Perform general ph ysical examination (Section [IP_ADDRESS])
Perform gy necological examination (with breast palpation ; Section [IP_ADDRESS])
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 36of 119
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform safet y laboratory  tests (including FSH )and urinaly sis(Section [IP_ADDRESS])
Test for 
Chlamydia; if positive, also test for gonorrhea (Section [IP_ADDRESS]).  A single 
repeat test is permissible if the screening results are positive.
Obtain cervical smear (Section [IP_ADDRESS]).  A cervical smear should be taken at this visit 
or a documented nor mal result (using the Bethesda sy stem or a corresponding s ystem) 
has to have been obtained within 6 months before the Screening Visit (Visit 1). 
Subjects with ASCUS can be included if they  have a HPV DNA test that, according to 
the standards of the local 
laboratory , is negative for high -risk HPV.  A c ervical smear 
may be repeated once if the screening result is abnormal.
9.2.3 Baseline – Visit 2
This section was changed in Amendment 1, see Section [IP_ADDRESS].
The following procedures and assessments will be done:
Re-
check inclusion/exclusion criteria (Sections 6.1 and 6.2)
Age at baseline (Section 9.3.1)
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform urine pregnancy test (Section [IP_ADDRESS])
Blood sample for PK (all subjects )(Section 9.5.1)
Subject satisfaction with Mirena 
(Section 9.7.4)
Interview for the following:
Concomitant medications (Section 8.1)
AEs (Section 9.6.1)
Dispense and explain the subject’s daily  eDiarydevice (
Section 9.7.1) , remind the 
subject to start the eDiary at the day  of the visit
(i.e. recording of uterine bleeding and 
back -up contraception )
Dispense home pregnancy  kits with instructions ( Section [IP_ADDRESS])
Dispense alkaline hematin kit with instructions for subjects in HMB group
9.2.4
6-month visit – Visit 3
The following procedures and assessments will be done:
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform urine pregnancy test (Section [IP_ADDRESS])
Blood sample for PK (Note: subjects randomized to this visit
) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section 8.1)
AEs (Section 9.6.1)
Continuing need for contraception (Section 9.7.1)
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 37of 119
Dispense home pregnancy  kits with instructions (Section [IP_ADDRESS] )
Review completed (monthly )eDiary , including information on uterine bleeding and 
back -up contraception.
Dispense alkaline hematin kit with instructions for subjects in HMB group
9.2.5
12-month visit – Visit 4 (End of Year 6 of Mirena use)
This section was changed in Amendment 1, see Section [IP_ADDRESS].
The following procedures and assessments will be done:
Assess vital signs and weight (Section [IP_ADDRESS] )
Perform general ph ysical examination (Section [IP_ADDRESS])
Perform gy necological exam ination (with 
breast palpation ; Section [IP_ADDRESS])
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform urine pregnancy test (Section [IP_ADDRESS])
Perform 
safety laboratory  test and urinal ysis(Section [IP_ADDRESS])
Blood sample for PK (Note: subjects randomized to this visit
) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section 8.1)
AEs (Section 9.6.1)
Continuing need for contraception (Section 9.7.1)
Dispense home pregnancy  kits with instructions ( Section [IP_ADDRESS])
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception.
Subject satisfaction with Mirena (Section 9.7.4).
9.2.6
18-month visit – Visit 5
The following procedures and assessments will be done:
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform urine pregnancy test (Section [IP_ADDRESS])
Blood sample for PK (Note: subjects randomized to this visit ) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section 8.1)
AEs (Section 9.6.1)
Continuing need for contraception (Section 9.7.1)
Dispense home pregnancy  kits wit
h instructions ( Section [IP_ADDRESS])
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception.
Dispense alkaline hematin kit with instructions for subjects in HMB group
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 38of 119
9.2.7 24 –month visit – Visit 6 (End of Year 7 of Mirena use)
The following procedures and assessments will be done:
Assess vital signs and weight (Section [IP_ADDRESS])
Perform general ph ysical examination (Section [IP_ADDRESS])
Perform gy necological examination (with breast palpation ; Section [IP_ADDRESS])
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform urine pregnancy test (Section [IP_ADDRESS])
Perform safet y
laboratory  test and urinal ysis(Section [IP_ADDRESS])
Blood sample for PK (Note: subject s randomized to this visit ) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section 8.1)
AEs (Section 9.6.1)
Continuing need for contraception (Section 9.7.1)
Dispense home pregnancy  kits with instructions ( Section [IP_ADDRESS])
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception
Subject satisfaction with Mirena (Section 9.7.4).
9.2.8
30-month visit – Visit 7
This section was changed in Amendment 1, see Section [IP_ADDRESS].
The following procedures and assessments will be done:
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform urine pregnancy test (Section [IP_ADDRESS])
Interview for the following:
Concomitant medications (Section 8.1)
AEs (Section 9.6.1)
Continuing need for contraception (Section 9.7.1)
Dispense home pregnancy  kits with instructions ( Section [IP_ADDRESS])
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception.
Dispense alkaline hematin kit with instructions for subjects in HMB group .
Discuss the contraceptive options available after the study  treatment with the subject (see 
Section 8.2).
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 39of 119
9.2.9 36- month visit, EOT – Visit 8 (End of Yea r 8 of Mirena use)
This section was changed in Amendment 1, see Section [IP_ADDRESS] .
The following procedures and assessments will be done:
Assess v ital signs and weight (Section [IP_ADDRESS] )
Perform genera l phy sical examination (Section [IP_ADDRESS])
Perform gy necological examination (with breast palpation ; Section [IP_ADDRESS])
Perform pelvic examination to visualize Mirena removal threads (
Section [IP_ADDRESS] )
Obtain cervical smear (Section [IP_ADDRESS])
Perform urine 
pregnancy test (Section [IP_ADDRESS] )
Perform safet y
laboratory  test and urinal ysis(Section [IP_ADDRESS])
Blood sample for PK ( all subjects ) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section 8.1)
AEs (Section 9.6.1)
Conti nuing need for contraception (Section 9.7.1)
Dispense home pregnancy kits with instructions (
Section [IP_ADDRESS])
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception.
Collect eDiary
device (Section 9.7.1)
Subject satisfaction with Mirena (Section 9.7.4)
Remove the Mirena (Section 9.7.3)
Complete Mirena removal ease (investigator) and pain (subject) assessment
9.2.10
3-week follow -up call (EOS)
All subjects will be contact[INVESTIGATOR_530] 3 weeks after EOT (i.e. after Mirena removal) to collect 
information on an y pregnancy detected shortl y after the end of study treatment , see Section 
9.4.1.
9.2.[ADDRESS_997314] -study pregnancies
This section was changed in Amendment 1, see Section [IP_ADDRESS].
Subjects who prematurely discontinued stud y treatment will be contact[CONTACT_730118] “pregnancy ”, “death”, or “withdrawal b y subject” where the 
subject h as withdrawn main consent during study
 conduct and wishes to stop future contact 
[CONTACT_36362]. For subjects that had withdrawn consent during stud y, but consented to post 
study  participation follow -up, post treatment pregnancy tracking information is expe cted.  At 
this time, subjects will be asked if they  have been pregnant after the study  (i.e. after the 3 -
week follow -up call). This contact [CONTACT_730119] -Treatment Pregnancy  Tracking (PTPT) 
process , see Section 9.4.1 .
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 40of [ADDRESS_997315] for return -to-fertility
This section was changed in Amendment 1, see Section [IP_ADDRESS] .
Subjects that prematurel y discontinued treatment due to ‘Wish for pregnancy’ will be 
contact[CONTACT_730120] 12 months after end of treatment 
(EOT, i.e. re moval of Mirena). If a subject was not pregnant at [ADDRESS_997316] was “Lost to 
Follow -up” at [ADDRESS_997317]-
Treatment Pregnancy  Tracking (PTPT) process, see Section 9.4.1.
9.3 Population characteristics
9.3.1 Demographic
This section was changed in Amendment 1, se e Section [IP_ADDRESS].
Demographic data [e.g. year of birth, age at the screening (Visit 1), age at baseline (Visit 2),
race, ethnic group, educational level] and other population characteristics including tobacco 
useand alcohol consumption will be collected at time points presented in Table 9–1.
9.3.2 Medical history
Medical history  findings (i.e. previous diagnoses, diseases or surgeries) meeting all criteria 
listed below will be collected as available to the investigator:
Start before signing of the informed consent 
Considered relevant fo r the subject’s study  eligibility
Any condition that is being stabilized by  [CONTACT_730121].  The medication 
being used should be recorded in the concomitant medication eCRF .
All new or worsened findings after signing the informed consent should be documented on 
the Adverse Event eCRF.
Detailed instructions on the differentiation between (i) medical history  and (ii) adverse events 
can be found in Section [IP_ADDRESS].
9.3.3 Reproductive and menstrual history
The reproductive and menstrual history  includes information on menarche, number of 
births
and pregnancies, number of ectopic pregnancies, absence of menstrual/withdrawal bleeding, 
intracy clic bleeding and on the average length of the cy cle.
9.3.4 Other baseline characteristics
[IP_ADDRESS] Indication for current Mirena
The subject must provide written documentation from the prescribing ph ysician on the 
indication for which the current Mirena was prescribed (contraception or contraception and 
heav y menstrual bleeding).  The indication is recorded in the eCRF.  In addition , subject must 
provide documentation o fthe date of Mirena insertion.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 41of 119
9.4 Efficacy
This section details the procedures for collecting data on efficacy  variables.  A concise listing 
of efficacy  variables is given in Section [IP_ADDRESS]. The complete list of variables to be anal yzed 
for this study  will be provided in the statistical analysis plan.
9.4.1 Occurrence of pregnancies
The occurrence of a pregnancy  (yes/no) is the primar y efficacy  variable in this study .
The sponsor will closely  monitor the occurrence of pregnancies (based on the expedited 
reporting of pregnancies by  [CONTACT_473]) throughout the study .  
[IP_ADDRESS] Pregnancies during the study
This section was changed in Amendm ent 1, see Section [IP_ADDRESS].
If a pregnancy  is detected anytime during the 
study , the subject is to discontinue her 
participation in the study .  
The investigator must report to the sponsor an y pregnancy occurring in a study  subject during 
her participation in this study including pregnancies detected at the contact 3 weeks after 
EOT.  This report is to be submitted within the same timeframe as an S AE (i.e. no later than 
24hours of having gained knowledge of the event), although a pregnancy , per se, is not 
considered an AE/SAE. 
The subject will be instructed to contact [CONTACT_43038] y site immediately  if a pregnancy  is suspected 
or detected.  In such a c ase, an unscheduled visit should be arranged for the subject as soon as 
possible and the investigator should confirm the pregnancy  by a valid method (e.g. 
ultrasound, serum hCG test).  If such confirmation cannot be achieved within 24hours of the 
subject contact[CONTACT_730122], the investigator must still report the pregnancy  to the 
sponsor and then follow -up with information once confirmation has been obtained.
A pregnancy  will be reported on the forms provided.  The investigator is required to 
docum ent, as far as possible, the estimated date of conception, calculated due date, the reason 
for pregnancy  (e.g., 
Mirena failure), location of the pregnancy , and, if applicable, the location 
of the Mirena and information regarding whether the Mirena was removed during the 
pregnancy .  The investigator is required to provide any  additional information (e.g. early  
termination) as soon as it becomes available.
All pregnancies occurring during the stud y (including those detected during the screening 
period) will b e followed for the final outcome of the pregnancy  for both the subject (mother) 
and fetus/child and documented on the forms provided .  Any  abnormal outcome of the mother 
or the child should also be reported as an SAE (e.g., spontaneous abortion, pre -term b
irth, 
elective abortion triggered by  [CONTACT_730123]).
[IP_ADDRESS] Pregnancies occurring after the end of study treatment
This section was changed in Amendment 1, see Sections [IP_ADDRESS] and [IP_ADDRESS].
All pregnancies detected up to [ADDRESS_997318] be reported to 
the sponsor; all subjects will be instructed to contact [CONTACT_730124].  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 42of [ADDRESS_997319] occurred during study  treatment (i.e. up to 7 day s after EOT) ,
further investigations will be conducted, and the pregnancy  should be re ported immediately  
and will be followed up according to the process described above for pregnancies during the 
study .
3-month follow -up contact:   [CONTACT_730125], subjects who prematurely  discontinued study  
treatment will be contact[CONTACT_730126] “pregnancy ”, “death”, or 
“withdrawal b y subject” where the subject has withdrawn main consent during stud y conduct 
and wishes to stop future contact [CONTACT_36362]
. For subjects that had withdrawn consent during 
study , but consented 
to post study  participation follow -up, post -treatment pregnancy  tracking 
information is expected and they will be contact[CONTACT_730127] [ADDRESS_997320] been pregnant after the study .  If 
subjects could not be contact[CONTACT_6811] 3 months, they  will be considered “Lost to Follow -
up”for 
post-study  pregnancy tracking .
12-month follow -up contact:   [CONTACT_730128] y discontinued treatment due to 
‘Wish for pregnancy ’ will be contact[CONTACT_730129] 1 y ear 
after end of 
treatment (EOT). If a subject was not pregnant at [ADDRESS_997321] was “Lost to 
Follow -up” at [ADDRESS_997322] be reported to the sponsor via electronic data 
collection tool (see Section 11.1).  In addition, if the estimated date of conception is suspected 
to have oc curred during study  treatment, the pregnancy  should be reported immediately  
according to t he process described under section [IP_ADDRESS] .
9.4.2 Assessment of menstrual blood loss (MBL) by [CONTACT_730130], the MBL will be assessed [ADDRESS_997323] 30 day s of the treatment period 
(starting at baseline visit, Visit 2) and for the 30 day s before visits 4, 6 a nd 8.  T he subjects in 
this subgroup will be required to use the selected types of sanitary  products (towels, tampons 
and pant y liners) provided by [CONTACT_730131] 4 periods. Subjects will return the us ed products to the study  site at two week intervals
, 
and all used sanitary  products will be sent to the central laboratory  for analy sis. Please see 
Table 9–2 for tim ing of the 4 periods and the required visits.
Details of the alkaline hematin method are given in the lab manual.
9.5 Pharmacokinetics / pharmacodynamics
9.5.1 Sample collection
Blood sample sfor the determination of LNG concentration sin plasma and sex hormone 
binding globulin (SHBG) concentrations in serum for population pharmacokinetic (popPK) 
analysis will be taken at several time points during the study  according to the schedule 
presented in Table 9–1.  A blood sample is taken from all subjects at baseline (visit 2) and at 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 43of 119
the EOT (visit 8; before Mirena is removed).  In addition, two blood samples per subjects will 
be taken during two of the treatment visits 3 – 6as outlined in more detail below . 
In case a subject prematurely  discontinues the study , a blood sample will be taken in addition ,
even if the 2 randomized sample s (visit 3 – 6) have alread y been taken at a previous visit. 
This sample will al ways be taken before Mirena is removed.  (If Mirena has been 
completely  expelled, no sample is needed.)
In order to achieve an approximately  equal distribution of blood samples over the whole 
treatment period, the time points at whic h the samples are tak en from each subject will be 
randomized.  This means that the sampling time points for each subject will be allocated to 
twoof the 4 treatment period visits ( visits 3 –6).  Subjects will be allocated to one of these 
sampling time points with the same pro babilit y, i.e., with the probability 1: 4.  The allocation 
of subjects to sample time points for popPK will be done using a computer generated 
randomization list.  The time point
sat which the sample sareto be taken from an individual 
subject can be found on the randomization list provided to the study  site.
The pharmacokinetic calculation will be based on the actual sampling time and dosing times. 
Deviations from the specified time points will be documented and taken into account when 
calculating the PK parameters. 
Details to the collection, processing, storage and shipment of samples will be provided in a 
separate document (e.g. Sample Handling Sheets or Lab Manual).
9.5.2 Drug measurements
The bioanal ytical anal yses will be performed under the supervision of the function Drug 
Metabolism and Pharmacokinetics, Bay er AG.
Determination of LNG in plasma and SHBG in serum
The anal yses of LNG concentrations in EDTA K 2plasma will be performed using a validated 
LC-MS/MS method. The determination of SHBG concentrations in serum samples will be 
performed using a validated immunoassay . Quality  control (QC) and calibration samples will 
be anal yzed concurrently with study  samples.  The results of LNG and SHBG concentrations 
as well as the results of calibration samples and QC samples will be reported in the 
Bioanal ytical Reports which will be included in the Clinical Study  Report for this study .
Additionally , representative study  samples may  be used for further pharmacokinetic anal yses, 
e.g. for a validation of a SHBG binding modeling compared to actual measurements.
9.5.3 Pharmacokinetic evaluation
Plasma L NG and SHBG concentration data collected during the study  will be an alyzed at the 
end of study  by [CONTACT_730132]. Mixed effects 
models, or population type models, describe the relationship between e.g. dose, time and 
pharmacological observations such as plasma /serum drug concen trations. Both structural and 
random effects are involved in this relationship. An existing population PK model will be 
applied to the data and refined to characterize the PK of L NGover the entire treatment period 
(during years 6 to 8) using individual LNG serum (or plasma) concentration s, SHBG serum 
concentrations and residual content measurements of LNG in the IUS
.Individual PK 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 44of 119
parameters of total and unbound L NG andSHBG as well as in vivo release rates will be 
calculated. The details of the anal ysis will be described in a separate Modeling & Simulation 
(M&S) Analy sis Plan and the results will be reported in a separate M&S Report.
9.5.4 Residual LNG content analysis
In order to evaluate the performance of Mirena during e xtended use , the residual content of 
LNG in used Mirena devices will be determined from all subjects at the end of treatment (i.e. 
from those who complete the 3 y ears in the study  and from those who discontinue the study  
treatment prematurel y).  All used Mirena devicesare to be sent to the sponsor’s 
representative.
9.6 Safety
9.6.1 Adverse events
[IP_ADDRESS] Definitions
Definition of adverse event (AE)
In a clinical stud y, an AE is any untoward medical occurrence (i.e. any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a patient or 
clinical investigation subject after providing written informed consent for participation in the 
study .  Therefore, an AE may  or may  not be temporally  or causally  associated with the use of 
a medicinal (invest igational) product.
A surgical procedure that was planned prior to the start of the study  by [CONTACT_433139] (however, the condition for which the surgery  is 
required may  be reported in the medical history or may  be an AE
, (see below ).
In the following differentiation between medical history  and AEs, the term “condition” may  
include abnormal e.g. physical examination findings, s ymptoms, diseases andlaboratory
findings
Conditions that started before signing of informed consent and for which no sy mptoms 
or treatment are present until signing of informed consent are recorded as medical 
history (e.g. seasonal allergy  without acute complaints).
Conditions that started before signing of informed consent and for which symptoms or 
treatment are present after signing of informed consent, at unchanged intensity , are 
recorded as medical history (e.g. allergic pollinosis) .
Conditions that started or deteriorated after signing of informed con sent will be 
documented as adverse events.  This i ncludes intercurrent illnesses.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 45of 119
Definition of serious adverse event (SAE)
An SAE is classified as any  untoward medical occurrence that, at an y dose, meets an y of the 
following criteria (a –f):
a.Results in death
b.Is life -threatening
The term ‘life -threatening’ in the definition refers to an event in which the subject was 
at risk of death at the time of the event, it does not refer to an event which 
hypothetically  might have caused death if it were more severe .
c.Requires inpatient hospi[INVESTIGATOR_1081] 
A hospi[INVESTIGATOR_209543]:
- The admission results in a hospi[INVESTIGATOR_730082] 12 hours
- The admission is pre- planned
(e.g. elective or scheduled surgery  arranged prior to the start of the study ; 
admission is part of the study  procedures as described in Section 9.2)
-The admission is not associated with an AE 
(e.g. social hospi[INVESTIGATOR_8933]).
However, it should be noted that invasive treatment during an y hospi[INVESTIGATOR_8934] c riterion of ‘medicall y important’ and as such may be reportable as an SAE 
dependent on clinical judgment.  In addition, where local regulatory  authorities 
specificall y require a more stringent definition, the local regulation takes precedence.
d.Results in 
persistent or significant disability  / incapacity
Disability  means a substantial disruption of a person’s ability  to conduct normal life’s 
functions.
e.Is a congenital anomal y / birth defect
f.Is another serious or important medical event as judged b y the inve stigator
Important medical events and medical review
An AE may  be considered serious because it may jeopardize the subject and may  require 
intervention to prevent another serious condition.  As guidance for determination of important 
medical events, the L ist of I mportant Medical Events (IME) developed and published by  
[CONTACT_16089]  (EMA) at 
(http://eudravigilance.ema.europa.eu/human/textforIME.asp) will be used in this study .  The 
list consists of terms that refer to or might be indicative of a serious disease state.  Such 
reported events warrant special attention because of their possible association with a serious 
disease state and may  lead to more decisive action than reports on other terms.
All non- serious AEs reported in this study  will be reviewed against the most current IME list 
periodicall y. Events that are contained on the IME list will be specifically reviewed b y the 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 46of 119
Study  Medical Expert, and if necessary , may  be queried. If needed, the Investigator will be 
asked to review and confirm whether or not the event meets the criteria for seriousness, in 
his/her opi[INVESTIGATOR_1649]. I n addition, the events listed in Section 9.6.3 will be medically  reviewed. An y 
non-serious event that, upon further review, is deemed to meet the seriousness criteria (see 
SAE criteria specified below) will be reported within 24 hours of the determination that it is 
considered serious.
Further details of the medical review to be conducted during the stud y are provided in a 
separate document, the Medical Review Plan (MRP ), which is to be finalized and signed prior 
to the First Patient First Visit (FPFV).
[IP_ADDRESS] Classifications for adverse event assessment
All AEs will be asse ssed and documented b y the investigator according to the categories 
detailed below.  
[IP_ADDRESS].[ADDRESS_997324] be determined according to the criteria given in 
Section [IP_ADDRESS].
[IP_ADDRESS].2 Intensity
The intensity  of an AE is classified according to the following categories:
-Mild
-Moderate
-Severe
[IP_ADDRESS].3 Causal relationship 
The assessment of the causal relationship between an AE and the administration of treatment 
is a decision to be made by  [CONTACT_093], who is a qualified phy sician, based on all 
information available at the time of the completion of the CRF.
Causality  should be assessed separatel y for each study treatment as detailed in the CRF. If the 
investigator feels that the event cannot be firml y attributed to one of the study treatments 
(e.g. owing to a suspected underly ing interaction), the same assessment will be documented 
for each study
 treatment.
The assessment is based on the questio n whether there was a “reasonable causal relationship” 
to the study  treatment in question.
Possible answers are “y es” or “no”
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 47of 119
An assessment of “no” would include:
1.The existence of a highl y likely  alternative explanation, e.g. mechanical bleeding at 
surgica l site.
or
2.Non-plausibility , e.g. the subject is struck by  [CONTACT_358041]; cancer 
developi[INVESTIGATOR_007] a few day s after the first drug administration.
An assessment of “y es” indicates that that the AE is reasonabl y associated with the use of the 
study  treatment.
Important factors to be considered in assessing the relationship of the AE to study  treatment 
include:
- The temporal sequence from drug administration:  The event sho uld occur after the drug 
is given.  The length of time from drug exposure to event should be evaluated in the 
clinical context of the event.
-Recovery  on drug discontinuation (de -challenge):  Subject’s response after de -challenge 
should be considered in view of the usual clinical course of the event in question.
-Underl ying, concomitant, intercurrent diseases:  
Each event should be evaluated in the context of the natural history  and course of the 
disease being treated and any  other disease the subject may  have.
-Concomitant medication or treatment: 
The other drugs the subject is taking or the treatment the subject receives should be 
examined to determine whether an y of them might have caused the event in question.
-Known response pattern for this class of dr
ug: Clinical/preclinical
-Exposure to phy sical and/or mental stresses: The exposure to stress might induce adverse 
changes in the recipi[INVESTIGATOR_23567] a logical and better explanation for the event
-The pharmacology  and pharmacokinetics of the study  treatme nt: 
The pharmacokinetic properties (absorption, distribution, metabolism and excretion) of 
the study  treatment, coupled with the individual subject’s pharmacody namics should be 
considered.
- The assessment is not possible
Causal relationship to protocol- required procedure s
The assessment of a possible causal relationship between the AE and protocol -required 
procedure(s) is based on the question whether there was a “reasonable causal relationship” to 
protocol -required procedure(s).
Possible answers are “y es” or “no”
[IP_ADDRESS].4 Action taken with study treatment 
Any action on study  treatment to resolve the AE is to be documented usi ng the categories 
listed below.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 48of 119
-Drug withdrawn
-Dose not changed
-Not applicable
-Unknown
[IP_ADDRESS].5 Other specific treatment(s) of adverse events
-None
-Remedial drug therap y
-Other
[IP_ADDRESS].6 Outcome
The outcome of the AE is to be documented as follows: 
-Recovered/resolved
- Recovering/resolving
-Recovered/resolved with sequelae
-Not recovered/not resolved
-Fatal
-Unknown
[IP_ADDRESS] Assessments and documentation of adverse events
Theinvestigator has to record on the respective eCRF pages all adverse events occurring in 
the period between the signing of the informed consent and the end of study ; after the end of 
the study there is no requirement to activel y collect AEs including death s.  The ty pe of 
information that should be assessed and recorded by  [CONTACT_303148] [IP_ADDRESS].  
“Death” should not
be recorded as an AE on the AE page.  Instead, “death” is the outcome of 
underly ing AE(s).
For all serious adverse events (SAEs) the sponsor has to carry out a separate assessment for 
expectedness, seriousness and causal relationship to study  drug.
The f ollowing events should not be reported as AEs/SAEs , unless (i) they are specificall y 
considered as such b y the investigator, according to the following conditions, or (ii) they  lead 
to withdrawal of a subject from the study .  This is to avoid redundancy  and/or inconsistent 
reporting of AEs as these data may  alread y be recorded in the CRF or subject’s eDiary.
Ovarian cysts:  An ovarian cy st should only  be reported as an AE if it is felt to be 
non-physiologic (at the discretion of the investigator).  Ultrasound examinations will 
not be routinely  scheduled as part of this study  but may  be performed by  [CONTACT_730133] .  If an ovarian cy st is diagnosed, follow -
upshould be in 
accordance with the investigator’s standard practice.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 49of 119
Findings on the bleeding diary:   Uterine bleeding (including intracy clic bleeding and 
absence of bleeding) should be recorded as an AE only  if:
it leads to study  discontinuation
it leads to therapeutic or diagnostic procedures
it is regarded as SAE
it show sa clinically  significant worsening during the study  that, in the 
judgment of the investigator, is not consistent with the expected clinical 
course, or are specifically reported as AEs b y the subject .
[IP_ADDRESS] Reporting of serious adverse events
The definition of serious adverse events (SAEs) is given in Section [IP_ADDRESS].  Each SAE must 
be fo llowed up until resolution or stabilization by  [CONTACT_303149][INVESTIGATOR_841].
Investigator’s notification of the sponsor
All investigators will be thoroughl
y instructed and trained on all relevant aspects of the 
investigator’s r eporting obligations for SAEs.  This information, including all relevant contact 
[CONTACT_8972], is summarized in the investigator site file.  This information will be updated as 
needed.
The investigator must report immediately  (within 24 hours of the investigator’s awareness) all 
SAEs occurring during the observation period defined in Section [IP_ADDRESS] to the recipi[INVESTIGATOR_730083].  For this, an 
AE page in the CRF as well as the complementary pages provided in the Investigator File 
must be completed for each SAE.  
SAEs occurring after the protocol -defined observation period will be processed by [CONTACT_23637].
Notification of the IECs / IRBs
Notification of the IECs / I RBs about all relevant events (e.g. SAEs, suspected, unexpected, 
serious adverse reactions [S[LOCATION_003]Rs]) will be performed by  [CONTACT_23638]/or by  [CONTACT_23639].
Notification of the authorities
The processing and reporting of all relevant events (e.g. SAEs, S[LOCATION_003]Rs) to the authorities 
will be done by  [CONTACT_23625].
Sponsor’s notification of the investigational site
The sponsor will inform all investigational sites about reported relevant events (e.g. S[LOCATION_003]Rs) 
according to all applicable regulations.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 50of 119
[IP_ADDRESS] Expected adverse events
For this study , the applicable reference document is the most current version of the 
investigator’s brochure (IB).
Overview listings of frequent events that have occurred so far in the clinical development are 
shown in the current IB.  If relevant new safety information is identified, the information will 
be integrated into an update of the IB and distributed to all participating sites.
The expectedness of AEs will be determined b y the sponsor according to the applicable 
reference document and according to all local regulations.
9.6.2 Pregnancies
The occurr ence of pregnancies is the primary  efficacy  variable in this study .  For further 
details, p lease refer to Section 9.4.1.
9.6.3 Further safety
[IP_ADDRESS] Vital signs and weight
Vital signs and bod y weight will be measured according to the schedule presented in Table 
9–
1.
Vital signs will include heart rate (for 1 minute, after 5 minutes in th e sitting position) and 
systolic and diastolic blood pressure (after 5 minutes in the sitting position). 
In case of clinicall y relevant deviations in vital signs, the values are to be confirmed b y 
repeated measurement before documentation.
The subject wil l be weighed on a scale, without shoes, and dressed with approximately  
similarly  heav y clothes at each appropriate visit (see Table 9–1 ).
[IP_ADDRESS]
Physical examination
A general phy sical examination should be conducted in accordance with the investigator’s 
standard practice at the time points shown in Table 
9–1.  
Any physical examina tion finding, s ymptom, or disease observed prior to signing the ICF 
should be recorded as medical history .  After signing the ICF, any  deterioration or new 
physical examination finding, s ymptom, or disease should be recorded as an AE/SAE.
Abnormal ph ysical examination findings are recorded either as medical history  or as adverse 
events (see Section [IP_ADDRESS]).
[IP_ADDRESS] Gynecological examination
Gynecological examination will be performed at visits specified in Table 
9–1.  During the 
gynecological examination, the investigator will examine the following: 
Breasts 
Vulva
Vagina
Cervix
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 51of 119
Uterus
Ovaries
Any gynecological examination finding, s ymptom, or disease observed prior to signing of the 
ICF should be recorded as medical history .  After signing of the ICF, any  deterioration or new 
gynecological examination finding, s ymptom, or disease shoul d be recorded as an AE/SAE 
(see Section [IP_ADDRESS] and [IP_ADDRESS]).
Please no
te that transvaginal ultrasound is not part of the gy necological examination, please 
see also Section [IP_ADDRESS].
[IP_ADDRESS] Pregnancy test
A urine pregnancy  test (urine hCG) will be performed at every  visit as presented in Table 
9–1.  
In case of a suspected pregnancy  at screening or baseline visits
, the subject must be 
withdrawn from the study and is considered a screening failure .  If a pregnancy  occurs during 
the study treatment period (i.e. after the baseline visit) , subjects should immediately  contact 
[CONTACT_730134] (for reporting of pregnancies, see also Section 9.4.1).  
During the course of the study , additional urine hCG testing should be performed if there is 
clinical suspi[INVESTIGATOR_1884] p regnancy  at an y time. 
In addition to the urine hCG tests performed b
y the site at each study visit, subjects will be 
provided with home urine pregnancy  tests to be used whenever a pregnancy  might be 
suspected.
If results of a home pregnancy  test are posit ive or if a subject is unsure whether she is 
pregnant after performing the test, she should immediately  contact [CONTACT_730135] a 
visit and have a confirmatory  test performed.
In the event of a positive urine hCG result, pregnancy  should be 
confirmed according to the 
local standard of care (e.g., serum hCG testing).  
[IP_ADDRESS] Cervical smear 
Cervical smear should be obtained following the standard practice of the study  site at the 
screening 
visit (Visit 1) if there is no documented normal result available within the previous 
[ADDRESS_997325] that, according to 
the standards of the local laboratory , is negative for high -risk HPV.  Cervical sme ar may  be 
repeated once during the screening period if screening results are abnormal.  After signing of 
the informed consent form , any  deterioration or new abnormalit y should be recorded as an 
AE.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 52of 119
[IP_ADDRESS] Test for Chlamydia
This section was changed in Amendment 1, see Section [IP_ADDRESS].
The subject will be tested for Chlamydia at the screening visit.  Chlamydia tests must be 
performed using a highl y accurat e test method (e .
g.the pol ymerase chain reaction [PCR] test, 
an example of nucleic acid amplification tests [NAAT]) in the central laboratory .
A single repeat test is permissible if the screening results are positive.  If the test result is 
positive, the subject must also be tested for gonorrhea.  Gonorrhea tests must also be 
performed using a highl y accurate test method that meets the standards of G LP.A subject 
with an active genital inf ection may  not be assigned to study  treatment until the infection has 
been successfull y treated (see Section 6.2, Exclusion criteri on 4).  
During the study , if asubject is found to have cervicovaginitis but not pelvic inflammatory  
disease, she should be treated 
keepi[INVESTIGATOR_730084] .
[IP_ADDRESS] Safety laboratory tests
This section was changed in Amendment 1, see Section [IP_ADDRESS].
Only  blood samples analy zed at the central laboratory  will be considered for anal ysis.  The 
name [CONTACT_730155] b y the vendor.  For a given laboratory  parameter, the acceptable values for inclusion 
would consist of values within the 
reference ranges, measured at baseline, as provided in the 
Covance Central Laboratory  Services (CCLS) Manual for Bay er Protocol [ZIP_CODE] ( Covance 
Project #: 518179). The safet y laboratory  tests may  be repeated once during the screening 
period if laboratory  values are outside the inclusion range and assessed as clinically  relevant.
The basic safet y laboratory includes:
Hematology :  leukocy tes, ery throcy tes, hemoglobin, hematocrit, mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH), platelets, neutrophils, eosinophils, basophils, 
lymphocy tes, monocy tes, gl ycosylated hemoglobin (HbA1c)
Serum chemistry :  creatinine, chloride, potas sium, sodium, calcium, total protein, albumin, 
total cholesterol, high density  lipoprotein (HDL) cholesterol, low densit y lipoprotein (LDL) 
cholesterol, trigly cerides, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
gamma -glutamy l transpe ptidase, alkaline phosphatase, and total bilirubin.
Follicle -stimulating hormone (FSH) (only at screening )
Urinalysis includes pH, urobilinogen, blood/hemoglobin, total protein, ketone, bilirubin, 
nitrite, glucose, and leukocy tes.
Repeat sampling and testi ng is permitted in the event th e sample quality  is deemed poor or 
inadequate .
In the event of implausible results, the laboratory  may  measure additional parameters to 
assess the quality  of the sample (e.g. clotted or hemoly zed) and to verify  the results.  The 
results from such additional anal yses may  neither be included in the clinical database of this 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 53of 119
study  nor evaluated further.  If the results are relevant, the investigator will be informed to 
determine follow -up activities outside of this protocol.
[IP_ADDRESS] Pres ence of Mirena removal threads
This section was changed in Amendment 1, see Section [IP_ADDRESS].
The presence of the removal threads will be checked at each study  visit and recorded in the 
eCRF .
The investigator will perform pelvic examinations at each stud y visit to verify  the presence of 
the Mirena removal threads in the appropriate location in the cervical os . If the presence of the 
removal threads cannot be verified, transvagi nal ultrasound (TVUS) is to be performed 
to 
verify  that the Mirena is in the appropriate intrauterine location and to exclude expulsion or 
perforation .  The subject should be instructed to periodicall y check the threads by  [CONTACT_730136] i f, at any  time of the study , a subject suspects 
that the Mirena may have been expelled, she should contact [CONTACT_730137] .  The subject should be instructed to use non -hormonal back -up method of 
contraception until it is confirmed that the Mirena is in the proper location.
Subject is in compliance with Mirena when:
Threads are visible, or,
Threads are not visible (or not checked) but TVUS performed to localize the Mirena
shows 
Mirena to be “I n situ” or “Displaced intrauterine”.
Subject is non-compliant with Mirena when:
Threads are not visible, and,
TVUS performed to localize Mirena shows that the IUS is “Partially  or totally  
expelled into vagina or cervical canal”, “Cervical perforation”, “M yometrial 
perforation”, “ Localization in the peritoneal cavity”, or “Absent”.
Threads are visible, but TVUS is perfor med for other reason(s) and Mirena
localization is recorded as “Partially  or totall y expelled into vagina or cervical canal”, 
“Cervical perforation”, “My ometrial perforation”, “ Localization in the peritoneal 
cavity ”.
Non-compliance with Mirena necessitates discontinuation of the subject from the study .  In 
case the IUS ispartially  expelled, it needs to be removed.  In case perforation has occurred, 
the IUS needs to be removed using appropriate procedures.
[IP_ADDRESS] Expulsion of Mirena
Total or partial expulsion of t he Mirena will be reported as an AE or SAE, as appropriate
(i.e. meets the criteria for an SAE as specified in Section [IP_ADDRESS]).
Total expulsion is confirmed if Mirena is observed in the vagina, it is not shown in the uterine 
cavity  by [CONTACT_2207], and/or the subject confirms that the sy stem was expelled.  If, upon 
pelvic examination, the removal thread(s) cannot be seen, expulsion should be considered and 
an ultrasound must be performed.  Possibilities of cervical or uterine perforations may  be 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 54of [ADDRESS_997326] discontinue study  treatment and 
the study .
[IP_ADDRESS] Perforation by [CONTACT_730138] (cervical or my ometrial perforations or 
perforations resulting in Mirena 
localization in the peritoneal cavit y) will be reported as SAEs .  
If a perforation is diagnosed, Mirena must be removed (this may  require further intervention 
such as h ysteroscop y or laparoscop y)and the subject must discontinue study  treatment and 
the study . 
[IP_ADDRESS] Pelvic inflammatory disease
All cases of pelvic inflammatory disease (PID) will be reported as an AE or SAE , as 
appropriate.
For the purposes of this study , a diagnosis of pelvic inflammatory  disease will be based on the 
following criteria : 
Presence of tenderness on pelvic examination and
Current lower abdominal pain and
At least 2 of the following findings:
Purulent or abnormal vaginal discharge 
Increased serum C -reactive protein ( 30mg/L ) 
Increased bod y temperature ( 38°C) 
Typi[INVESTIGATOR_730085] , if other clinical evidence is controversial
Evidence of causative pathogen (e.g., Chlamydia trachomatis or Neisseria 
gonorrhea) in the cervical canal
Ifpelvic inflammatory  disease is not successfully  treated, Mirena must be removed and the 
subject must discontinue the study . 
The pelvic inflammatory  disease eCRF and AE eCRF will be completed in all cases of pelvic 
inflammatory  disease.  If classified as an SAE, the appropriate forms will be completed and 
the sponsor’s local pharmacovigilance unit notified.  Details regarding notification to the 
Sponsor’s local pharmacovigilance unit are provided in Section [IP_ADDRESS].
[IP_ADDRESS] Uterine bleeding
This section was changed in Amendment 1, see Section [IP_ADDRESS].
The occurrence of uterine bleeding will be recorded every  day during the treatment phase 
using eDiaries provided by
 [CONTACT_456].  The recording will start at the baseline visit and will 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 55of [ADDRESS_997327] 24 hours on a daily  basis according to thebleeding intensity  definitions presented 
in Table 
9–3.
Table 9–
3 Uterine bleeding –bleeding intensity definitions –amended
Category Intensity Bleeding 
Intensity 
CodeDefinition
None None 1 No uterine bleeding
Spotting Spotting 2 Less than associated with normal menstruation relative to the 
woman’s experience, with no need for sanitar y protection 
except for panty liners
Bleeding Light 3 Less than associated with normal menstruation relative to the 
woman’s experience, with need for sanitar y protection
Normal 4 Like normal menstruation relative to the woman’s experience
Heavy 5 More than normal menstruation relative to the woman’s 
experience
9.7 Other procedures and variables
9.7.1 eDiary
This section was changed in Amendment 1, see Section [IP_ADDRESS] .
Patient- reported outcomes (PROs) will be collected using an electronic diary  (eDiary ).  
Recording of the uterine bleeding is the main part of the eDiary . The use of back
-up 
contraception will also be documented within the same eDiary .  Recall time will be [ADDRESS_997328] on how to use the device at 
the baseline visit .  At all the following visits (see Table 9–1) , the eDiary  entries will be 
checked and documented by [CONTACT_730139].  The investigator or 
designee and the on -site CRA will regularl y review the eDiary entries vi
a an internet -based 
application.  The eDiary  device will be returned at the end-of- treatment visit (Visit 8).
9.7.[ADDRESS_997329]/visit.
9.7.3 Mirena removal –assessment of the ease of the procedure (by 
[CONTACT_1697]) and pain during the removal (by [CONTACT_1130])
The assessments described here have been developed by  [CONTACT_730140]’s IUSstudies.  
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 56of [ADDRESS_997330] should not be recorded as an 
AE unless specifically  considered as such by  [CONTACT_093].
The ease of Mirena removal will be evaluated b y the investigator as eas y, slightly difficult or 
very difficult, and recorded in the eCRF.  The use of painkillers, (para)cervical blockade or 
dilation will be documented by  [CONTACT_730141].
Information regarding the Mirena removal procedure will be collected on the Mirena 
Removal Ease (b y investigator) and Pain (b y subject) eCRFs.
Please see also Section 7.6about reporting of technical complaints.
9.7.[ADDRESS_997331] satisfaction w ith Mirena
This section was changed in Amendment 1, see Section [IP_ADDRESS] .
At baseline visit, visit 4,6 and a t the end of the treatment (EOT, visit 8)(see also Table 9–1), 
the subject is asked to evaluate her satisfaction with the Mirena on a [ADDRESS_997332] the use of an y back -up contraception (e.g. use of condoms 
for protection against sexually  transmissible infections [STI s]) in their diaries. The onl y back -
up contraception allowed during stud y treatment is the use of a barrier method (e.g. condoms).
Please see also Section 7.4.1
9.8 Appropriateness of procedures / measureme nts
The procedures chosen to measure the variables of this study  are standard and/or widel y used ,
and generally  recognized as reliable, accurate, and relevant.
10. Statistical methods and determination of sample size
10.1 General considerations
Statistical analy seswill be conducted by  [CONTACT_43754]’s study  
statistician, 
except for the anal ysis of PK/PD data, which will be planned, performed and 
reported under the supervision of the sponsor´s pharmacometrics grou p. Statistical analysis 
willbe performed using SAS; the version used will be specified in the statistical anal ysis plan.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 57of 119
10.2 Analysis sets
This section was changed in Amendment 1, see Sections [IP_ADDRESS], [IP_ADDRESS] and [IP_ADDRESS] .
The documentation of important deviations and the assignment of subjects to analy sis sets 
will be performed according to t he CRO’s applicable Standard Operating Procedures and/or 
Instruction Manuals.  
The following statistical anal ysis sets will be defined:
Full analysis set (FAS) : 
All women who completed the baseline visit of the study
Primary analysis set Year 6 (PAS year 6) :
All women in the FAS with an age of 35 years or younger at baseline visit ( i.e. an age of 36 or 
younger at end of y ear 6)
Primary analysis set Year 7 (PAS year 7) :
All women in the FAS with an age of 34 years or y ounger at baseline visit (i.e. an age of 36 or 
younger at end of y ear 7)
Primary analysis set Year 8 (PAS year 8) : 
All women in the FAS with an age of 33 years or y ounger at baseline visit (i.e. an age of 36 or 
younger at end of y ear 8)
Safety analysis set (SAF) :
All women who completed the baseline visit of the study , anal yzed for the FAS.
The age at baseline (requir ed for PAS y ear 6, PAS y ear 7 and PAS y ear 8) will be used as 
recorded at the baseline visit 2.  
10.3 Variables and planned statistical analyses
This section was changed in Amendment 1, see Section [IP_ADDRESS].
In order to allow some flexibility
, the baseline visit is planned to take place 14 to 0 day s 
before the end of Year 5 of Mirena use (see Table 9–1). As a consequence, it is expected there 
will be various subjects with that baseline visit taking place prior to the start of ‘extension 
treatment period’, i.e. Day 1 of Year 6 of Mirena use. 
Variables collected on an ongoing basis will primarily  be anal yzed for the ‘extension 
treatment period’ starting at Day  1 of Year 6 of Mirena use , i.e., data collected between the 
baseline visit and Day  1 of Year 6 of Mirena use will be excluded : 
Primary  efficacy  variable, i.e. occurrence of pregnancies (section [IP_ADDRESS])
Main safet y variable, i.e. adverse events (section [IP_ADDRESS].1) 
Uterine bleeding / bleeding pattern (section [IP_ADDRESS].2) 
Variables collected at pre -specified 
visits /timeframes only will be analy zed per visit (unless 
otherwise stated) : 
Secondary  efficacy  variable, i.e. menstrual blood loss (section [IP_ADDRESS]) 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 58of 119
Other safety  variables, not listed above (section [IP_ADDRESS].3 ) 
Other variables (section [IP_ADDRESS]) 
More details will be provided in the statistical analysis plan.
10.3.1
Variables
[IP_ADDRESS] Efficacy variables
[IP_ADDRESS].1 Primary efficacy variable
This section was changed in Amendment 1, see Section [IP_ADDRESS] and [IP_ADDRESS].
The primary  efficacy  variable is the occurrence of pregnancy  within y ears 6 thru 8 of Mirena 
use.However, for the analy sis after 6 y earsof Mirena use , the primary  efficacy  variable is the 
occurrence of pregnancy  within y ear 6 of Mirena use, and forthe anal ysis after 7 y ears, the 
primary  efficacy  variable is the occurrence of pregnancy  within y ears 6 thru 7 of Mirena use. 
The Pearl Index ( PI)is defin ed as the number of pregnancies per 100 woman y ears. The Pearl 
Index will be analy zed for the ‘extension treatment period’ starting at Day  1 of Year 6 of 
Mirena use , i.e., exposure and pregnancies between the baseline visit and Day 1 of Year 6 of 
Mirena us e will be excluded
. The following PIs will be calculated:
'1-year PI ’(sixth y ear)', PI  [INVESTIGATOR_730086], i.e., number of 
pregnancies that occurred during the sixth y ear of treatment divided by  [CONTACT_730142] y ear of treatment.
'2-year PI ’(sixth and seventh y ear)', PI [INVESTIGATOR_730087], i.e., number of pregnancies that occurred during the sixth and seventh y ear 
of treatment divided b y time the women were under risk of getting pregnant in the 
sixth and seventh y ear of tr eatment.
'3-year PI ’(sixth, seventh 
and eighth y ear)', PI [INVESTIGATOR_730088], seventh and 
eighth year of treatment, i.e., number of pregnancies that occurred during the sixth, 
seventh and eighth year of treatment divided b y time the women were under a risk of 
getting pregnant in the sixth, seventh and eighth year of treatment.
Furthermore, the following PI [INVESTIGATOR_730089], i.e., exposure and pregnancies between the baseline visit and Day  1 of Year 6 of Mirena 
use will be included: 
'Overall PI', PI [INVESTIGATOR_730090] , i.e., number of pregnancies that 
occurred during the entire study  period starting at baseline visit divided by  [CONTACT_730143] a risk of getting pregnant.
The exact rules regarding how the exposure time w
ill be calculated are given in S ection 
[IP_ADDRESS]. 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 59of 119
[IP_ADDRESS].2 Secondary efficacy variables
Secondary  efficacy  variables are:
Menstrual blood loss (MBL) during a 30 -day period starting at the baseline visit and at 
the end of Years 6, 7 and 8.  MBL will be measured by  [CONTACT_112744].
The assessment of this variable is restricted to women who had M irena inserted for 
HMB.
Categorized menstrual blood loss (MBL) (>= 80 ml per 30 day s) at e nd of Year 6, 7 
and 8. The assessment of this variable is restricted to women who had M irena inserted 
for HMB.
[IP_ADDRESS] Safety variables
This section was changed in Amendment 1, see Section [IP_ADDRESS] and [IP_ADDRESS].
The main safet y variable is the incidence of treatment
-emergent adverse events (both serious 
and non- serious). Treatment- emergent AEs are defined as an y AEs occurring during the 
‘extension t reatment period’ starting at Day  1 of Year 6 of Mirena use .
Other safety  variables are: 
Uterine bleeding / Bleeding pattern 
Vital signs and weight
Cervical smear 
Test for Chlamy dia
Safety  laboratory  parameters
Presence of Mirena removal threads
Mirena expulsion rate
Mirena perforation rate 
[IP_ADDRESS] Other variables
Other variables are: 
Pharmac okinetic parameters 
Residual L NG content
Discontinuation rate
Subject satisfaction
Mirena removal: Ease and pain
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 60of 119
10.3.2 Statistical methods
[IP_ADDRESS] Analysis of the p rimary variable
This section was changed in Amendment 1, see Sections [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS] , 
and [IP_ADDRESS].
The primary  variable is the occurrence of pregnancy  within y ears 6- 8 of Mirena use.
However, 
for the anal ysis after 6 y ears, the primary  variable is the occurrence of pregnancy  
within y ear 6 of Mirena use, and forthe anal ysis after 7 y ears, the primary variable is the 
occurrence of pregnancy  within y ears 6 thru 7 of Mir ena use.
Definitions for PI s are presented in Table 10–1. 
Table 10–
1Definition of crude exposure times –amended
PI [INVESTIGATOR_730091]/ continuation 
statusCrude exposure time
1-year PI 
(6th year)Total expulsion Date, when expulsion was discovered – Date of D ay 1 Year 6
+1
Partial Expulsion/ 
Mirena removalDate of Mirena removal – Date of D ay 1 Year 6 +1
Pregnancy Date of conception – D ate of D ay 1 Year 6 +[ADDRESS_997333] to Follow up Maximum of (Date Mirena last known in situ – Date of D ay 1 
Year 6 +1; 1 day )
Continues into 7 th year 
of treatment365days
2-year PI 
(6th and 
7th year)Total expulsion Date, when expulsion was discovered – Date of D ay 1 Year 6
+1
Partial Expulsion/ 
Mirena removalDate of Mirena removal –Date of Da y 1 Year 6 +1
Pregnancy Date of conception – D ate of D ay 1 Year 6 +[ADDRESS_997334] to Follow up Maximum of(Date Mirena last known in situ – Date of D ay 1 
Year 6 +1; 1 day )
Continues into 8 th year 
of treatment730 day s
3-year PI 
(6th, 7th 
and8th 
year)Total expulsion Date, when expulsion was discovered –Date of Da y 1 Year 6
+1
Partial Expulsion/ 
Mirena removalDate of Mirena removal – Date of D ay 1 Year 6 +1
Pregnancy Date of conception – D ate of Day 1 Year 6 +[ADDRESS_997335] to Follow up Maximum of(Date Mirena last known in situ – Date of D ay 1 
Year 6 +1; 1 day )
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 61of 119
PI [INVESTIGATOR_730091]/ continuation 
statusCrude exposure time
Continues into 9 th year 
of treatmentMinimum of(1095 days ;Date of EOT vis it –Date of Day 1
Year 6 +1) 
Overall PI [INVESTIGATOR_730092], when expulsion was discovered –Baseline visit date + 1
Partial Expulsion/ 
Mirena removalDate of Mirena removal –Baseline visit date +1
Pregnancy Date of conception – Baseline visit date +[ADDRESS_997336] to Follow up Maximum of(Date Mirena last known in situ –Baseline visit 
date +1 ; 1 day )
Continued until EOT Date of EOT visit –Baseline visit date +1
A pregnancy  will be allocated to the time period(s) that are relevant for the calculation of the 
PIs described above, e.g., a pregnancy  that occurs on day  400 will be relevant for the 7thyear 
PI, the two years PI (
6th and7th y ear), the three years PI ( 6th, 7th and8th y ear), and the 
overall PI. Pregnancies that occur before Day  1 Year 6 of Mirena use will not count for 
the 1-
yearPI, 2-year PI [INVESTIGATOR_1238] 3 -year PI .  Pregnancies that occur after the Mirena was removed or an 
expulsion was realized will not count for any  PI. 
It should be noted that e.g., pregnancies that occur after partial expulsion, but before Mirena
removal will count for the PIs. 
Furthermore, it should be noted that pregnancies that occur within 7 day s after the end of 
exposure will count for the PI s. 
Exposure times to be subtracted: 
Subjects who apply  additional concomitant contraception are not in risk or are under a lower 
risk of getting pregnant than subjects who do not apply  additional contraception. I n case a 
subject uses concomitant contraceptive methods (e.g., condoms to prevent STD) ;the 
respective 28-day reference period (s)of additional contraceptive method us e will be excluded 
from the exposure time , unless a pregnancy  occurred in that 28 -day reference period .
Primary analysis
The primary  method for the evaluation of the occurrence of pregnancy  is the Pearl index 
defined as the number of pregnancies per 100 w omen y ears.
The PI s and the corresponding 2-sided 95 % confidence interval (CI) will be calculated using 
the model specified below. 
Mathematical model for the calculation of the PI :
[INVESTIGATOR_730093] a Poisson -distribution, the point estimate 
and the 95 % CI for the PI [INVESTIGATOR_730094]:
PI = x/E, 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 65of 119
[IP_ADDRESS].2 Bleeding pattern
This section was changed in Amendment 1, see Sections [IP_ADDRESS], [IP_ADDRESS] , and [IP_ADDRESS] .
Bleeding diary  data during the ‘extension treatment period’ starting at Day  1 of Year 6 of 
Mirena us ewill be anal yzed acc ording to the sponsor’s Best Practice Document entitled 
“Recording and evaluation of bleeding dat a”. Bleeding diary  data prior to the ‘extension 
treatment period’ will not be included in the anal yses. The handling of partial or missing data 
and detailed imputation rules will be described in the s tatistical analysis plan.
Bleeding intensit ywill be recorded b y the subject on a daily  basis using the categories 
presented in Table 9–3in section [IP_ADDRESS] .
In addition to absolute number of bleeding day s, bleeding/spotting epi[INVESTIGATOR_730095]’s Bleeding Intensity  Codes and the World Health 
Organization (WHO) definitions as provided in Table 10–2.
Table 10–
2Bleeding Intensity Codes and WHO Definitions for Bleeding Intensit y
–amended
Bleeding 
Intensity
CodesWHO Definitions
2 - 5 Bleeding/spotting epi[INVESTIGATOR_1865]: Day(s) with bleeding/spotting preceded 
and followed by [CONTACT_2669] 2 bleeding- free 
days.
2 Spotting -only epi[INVESTIGATOR_1865]: Day(s) with spotting preceded and followed 
by [CONTACT_2669] 2 bleeding -free days.
1 Bleeding/spotting -free interval: At least 2 days without bleeding/spotting 
preceded and followed by [CONTACT_2669] 1 
bleeding/spotting day.
In addition to the WHO definitions, a bleeding epi[INVESTIGATOR_730096] (s) with 
bleeding/spotting of which at least one day  is of intensity  [ADDRESS_997337] 2 bleeding -free day s.
In the following example (Table 10–3) of an assessment of bleeding epi[INVESTIGATOR_730097] a single bleeding ep isode
or multiple bleeding epi[INVESTIGATOR_1841] .  In Table 10–3, each recorded bleeding event consists of [ADDRESS_997338] and for each 
period, the number of bleeding/spotting day s and bleeding/spotting epi[INVESTIGATOR_615901]
.  If the bleeding intensity is recorded as light, normal or hea vy, this will be 
considered as ‘ bleeding ’.
For each subject and for each 28- day reference period and each 90- day reference period, the 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 67of 119
[IP_ADDRESS].3 Other safety variables
All other safet y variables will be anal yzed descriptive ly using summary  statistics or frequency  
tables as appropriate.
[IP_ADDRESS] Other variables
[IP_ADDRESS].1 Pharmacokinetic parameters
Pharmacokinetic data collected during the study  will be analy zeddescriptively . 
Population PK analy sis will be performed as described in a separate M&S Analy sis Plan and 
reported in a separate M&S Report
. 
[IP_ADDRESS].2 Residual LNG content
Residual L NG content will be analy zeddescriptively . 
[IP_ADDRESS].[ADDRESS_997339] Mirena removed due to partial expulsion or perforation, plus 
those who discontinue study  treatment for other reasons.  The Kaplan-Meier estimate will be 
used.
[IP_ADDRESS].[ADDRESS_997340] ’ssatisfaction with the Mirena on a 5-point scale (very  satisfied, somewhat 
satisfied, neither satisfied or dissatisfied, dissatisfied, very  dissatisfied) will be summarized 
descriptivel y.
[IP_ADDRESS].5 Mirena removal: ease and pain
The ease of Mirena removal ( easy, slightly difficult
,very difficult) will be s ummarized 
descriptivel y. 
The pain during the removal (none, mild, moderate, severe) will be summarized descriptively . 
10.[ADDRESS_997341] 200 
women co mpleting the 8th y ear of treatment with Mirena. With an estimated dropout rate of 
15%, the total number of women to be enrolled into the study  treatment phase would be 350.
In order to account for women excluded from the primary  anal ysis due to age restric
tions (i.e. 
women 34 y ears of age at baseline or older will not be included in the primary  anal ysis set 
‘PAS y ear 8’ for the final anal ysis after 8 y ears)2, the total number of women to be enrolled 
into the study  treatment phase is 360.
                                                
2It is assumed a bout 90% of women enrolled will be 18 to 32 years of age at screening, i.e. 10 % of w omen will 
be 33to 35 years oldand accordingly less will be 34 to 35 years old.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 69of 119
11. Data handling and quality assurance
11.1 Data recording
This section was changed in Amendment 1, see Section [IP_ADDRESS].
The data collection tool for this study  will be eCRF; a validated electronic data capture s ystem 
called RAVE.  Subject data necessary  for analy sis and reporting will be entered/transmitted 
into a validated database or data s ystem 
(e.g.CIE/TOSCA; SAS).  
Data will be entered b ysite personnel into an internet based electronic data capture software 
system RAVE, which Covance has licensed from Medidata Solutions Worldwide. RAVE has 
been validat ed by [CONTACT_730144].  
RAVE allows for the application of software logic to set -up data entry  screens and data 
checks to ensure the completeness and accuracy  of the data entered.  Covance extensivel y 
applies the logic to ensure data are complete and reflect the requirements of the study .  
Queries resulting from the application of the software logic are resolved b y site personnel.  
The data are stored at a secure host facility  maintained by  [CONTACT_51580] S olutions Worldwide and 
transferred on a periodic basis to Covance 's internal computer s ystem via a secure Virtual 
Private Network.
Access to RAVE is through a password -protected securit y system.  All personnel are 
thoroughl y trained before acquiring access to the sy stem .  Training records are maintained.
Personnel with access to RAVE are supported b y a Service Desk to answer questions and 
ensure access is maintained such that data entry  can proceed in a timely  manner.
RAVE contains a s ystem-generated audit trail that captures any  changes made to a data field, 
including who made the change, wh y it was change d,and the date and time it was made.  This 
information is available both at the investigator’s site and at Covance .  
Data entries are supported by  [CONTACT_730145]. A source 
document checklist will be used at the site to identify  the source data for key  data points 
collected and the monitor will work with the site to complete this.
Source documentation
The site must implement processes to ensure availability  of all required source 
documentation.  A source document checklist (not part of this protocol) will be used at the 
site to identify  the source data for key  data points collected and the m onitor will work with the 
site to complete this.
It is the expectation of the sponsor that all data entered into the CRF has source 
documentation available at the site except for the data listed below which will be entered 
directly  into the CRF; thus, thes e CRF data will be the source and no additional source 
documentation will be available.  The data entered directly
 into the CRF is not needed for the 
subject’s routine medical care.
data fields to be completed directl y in the eCRF : 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 70of 119
assessments on Mirena r emoval by  [CONTACT_1130] (pain) and investigator (ease of 
removal) , and 
subject ’ssatisfaction with Mirena.
These will be entered into eCRF by [CONTACT_31691].
eDiary data
The eDiary  entries will be considered as primary source data.
Data recorded from screeni ng failures
At minimum, the following data should be recorded in the CRF:
Demographic information (subject number; year of birth /age; if applicable race / 
ethnicity )
Date for Mirena insertion
Indication for Mirena
Reproductive and menstrual history
Date of informed consent
Relevant inclusion/exclusion criteria
Reason for premature discontinuation
Date of last visit.  
These data will be transferred to the respective database.
For screening failures with an SAE or pregnancy (see also section 9.4.1) , the following data 
should be collected in the CRF in addition to the data specified above:
All information related to the SAE /pregnancies such as: 
The SAE itself / pregnancy  test evaluatio n page
Concomitant medication
Medical history
Other information needed for SAE complementary  page
11.2 Monitoring
In accordance with applicable regulations, GCP, and sponsor’s/CRO’s procedures, monitors 
will contact [CONTACT_23988], 
study  requirements, and their responsibilities to satisfy  regulatory , ethical, and sponsor’s 
requirements.  When reviewing data collection procedures, the discussion will also include 
identification and documentation of source data items.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 71of 119
Thesponsor /designee will monitor the site activity  to verify  that the:
Data are authentic, accurate and complete.  
Supporting data may  be requested (example: blood glucose readings to support a 
diagnosis of diabetes). 
Safety  and r ights of subjects are being protected
Study  is conducted in accordance with the currently  approved protocol 
(including stud y treatment being used in accordance with the protocol)
Any other study  agreements, GCP, and all applicable regulatory  requirements are met.
The investigator and the head of the medical institution (where applicable) agrees to allow the 
monitor direct access to all relevant documents.
11.3 Data processing
Data will be collected as described in Section 11.1.  Clinical data management will be 
performed in accordance with applicable sponsor’s/CRO’s standards and data cleaning 
procedures.  This is app licable for data recorded on eCRF as well as for data from other 
sources (e.g. laboratory , ePRO).
For data coding (e.g. AEs, medication), internationally  recognized and accepted dictionaries 
will be used.
After its initial release for biometrical anal ysis,the clinical database is planned to be re -
opened for the inclusion of the following additional data: e.g.pharmacokinetic data , residual 
content data and post study  pregnancy tracking data . 
11.[ADDRESS_997342] important is to avoid missing data, e.g. b y monitoring in time for completeness (see 
Section 11.2) and investigators’ training, especially by [CONTACT_730146]. If the subject is unable to come to on -site visit 
during the allotted timeframe, the visit may  be documented via phone as described at Section 
6.4.[ADDRESS_997343] as much data as possible
. In addition, for completing the eDiary , 72-
hour recall time is implemented to allow some flexibility  for eDiary  completion and to avoid 
missing eDiary  data .
11.5 Audit and inspection
To ensure compliance with GC P and regulatory  requirements, a member of the sponsor’s (or a 
designated CRO’s) quality  assurance unit may  arrange to conduct an audit to assess the 
performance of the study at the study  site and of the study  documents originating there.  The 
investigator /institution will be informed of the audit outcome.
In addition, inspections by [CONTACT_8993](s)/I RB(s) are 
possible.  The investigator should notify  the sponsor immediately  of any  such inspection.
The investigator/ins
titution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 72of [ADDRESS_997344] that ensures that they  
are readil y available upon authorities’ request.
Patient (hospi[INVESTIGATOR_307]) files will be archived according to local reg ulations and in accordance with 
the maximum period of time permitted by [CONTACT_5035][INVESTIGATOR_307], institution or private practice.  Where 
the archiving procedures do not meet the minimum timelines required b y the sponsor, 
alternative arrangements must be made to ensur e the availability  of the source documents for 
the required period.
The investigator/institution notifies the sponsor if the archival arrangements change 
(e.g. relocation or transfer of ownership).
The investigator site file is not to be destroy ed without the sponsor’s approval.
The contract with the investigator/institution will contain all regulations relevant for the stud y 
center.
12. Premature termination of the study
The sponsor has the right to close this study  (or, if applicable, individual segments ther eof 
[e.g. treatment arms; dose steps; centers]) at an y time, which may be due but not limited to the 
following reasons: 
If risk -benefit ratio becomes unacceptable owing to, for example,
Safety  findings from this study  (e.g. SAEs)
Results of any  interim an alysis
Results of parallel clinical studies
Results of parallel animal studies 
(on e.g. toxicity , teratogenicity , carcinogenicity  or reproduction toxicity ).
If the stud y conduct (e.g. recruitment rate; drop -out rate; data qualit y; protocol 
compliance) doe s not suggest a proper completion of the trial within a reasonable time 
frame.
The investigator has the right to close his/her center at an y time.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 73of 119
For an y of the above closures, the following applies:
Closures should occur only  after consultation between involved parties.  Final decision 
on the closure must be in writing.
All affected institutions (e.g. IEC(s)/IRB(s); competent authority(ies); study center; 
head of stud y center) must be informed as applicable according to local law.
All study  materials (ex cept documentation that has to remain stored at site) must be 
returned to the sponsor.  The investigator will retain all other documents until 
notification is given b y the sponsor for destruction.
In the event of a partial study  closure, ongoing subjects, including those in post study  
follow -up, must be taken care of in an ethical manner.
Details for individual subject's withdrawal can be found in Section 6.4.1.
13. Ethical and legal aspects
13.1 Investigators and other study personnel
This section was changed in Amendment 1, see Section [IP_ADDRESS]
The name [CONTACT_3669] [CONTACT_31036]’s Study
 Medical Expert [INVESTIGATOR_730154] 1.  The co- ordinating investigator who will be responsible for signing the CSR, is 
(study  center #  
Allother study  personnel not included in 
this section are identified in a separate personnel list (not part of this clinical study  protocol) 
as appropriate.  This list will be updated as needed; an abbreviated version with personnel 
relevant for the centers will be available in each center’s investigator site file.
Whenever the term ‘investigator’ is noted in th e protocol text, it may  refer to either the 
principal investigator [INVESTIGATOR_8921], or an appropriately  qualified, trained and delegated 
individual of the investigational site.
The principal investigator [INVESTIGATOR_246183] (e.g. health authority , ethics committee, sponsor) 
before subject recruitment may  start at the respective center.  Likewise, all amendments to the 
protocol must be signed by  [CONTACT_458] [INVESTIGATOR_358000].
Acomplete list of all participating centers and their investigators, as well as all required 
signature [CONTACT_9002], will be maintained in the sponsor’s study  file.
The global sponsor of this study is identified on the title page of this protocol.  I f required by  
[CONTACT_1769], local co -sponsors will be nominated; they  will be identified on the respective 
country -specific signature [CONTACT_1787].
13.2 Funding and financial disclo sure
Funding
This study  will be funded by  [CONTACT_23662].
[COMPANY_003]
[COMPANY_003]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 74of 119
Financial disclosure 
Each investigator (including principal and/or an y sub investigators) who is directly  involved 
in the treatment or evaluation of research subjects has to provide a financial disclosure 
according to all applicable legal requirements.  All relevant documentation will be filed in the 
trial master file.
13.[ADDRESS_997345], evaluation, and 
documentatio n of this study , are designed to ensure that the sponsor and investigator abide by  
[CONTACT_23663] (GCP) guidelines and the guiding principles detailed in the 
Declaration of Helsinki.  The study  will also be carried out in keepi[INVESTIGATOR_730098](s) and regulation(s).
Documented approval from appropriate IEC(s)/IRBs will be obtained for all participating 
centers/countries before start of the study, according to GCP, local laws, regulations and 
organizations.  When necessary , an extension, a mendment or renewal of the I EC/IRB 
approval must be obtained and also forwarded to the sponsor.  The responsible unit (e.g. 
IEC/IRB, head of the study center/medical institution) must supply  to the sponsor, upon 
request, a list of the IEC/IRB members invol ved in the vote and a statement to confirm that 
the IEC/I RB is organized and operates according to GCP and applicable laws and regulations.
Strict adherence to all specifications laid down in this protocol is required for all aspects of 
study  conduct; the investigator may  not modify  or alter the procedures described in this 
protocol.  
Modifications to the study  protocol will not be implemented by  [CONTACT_23664].  However, the investigator or the sponsor may  
implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) 
to the trial subjects without prior IEC/I RB/sponsor approval/favorable opi[INVESTIGATOR_1649].  As soon as 
possible, the implemented deviation or change, the reasons for it and if appropriate the 
proposed protocol amendment should be submitted to the I EC/IRB/head of medical 
institution/sponsor.  Any  deviations from the protocol must be explained and documented by  
[CONTACT_093].
Details on discontinuation of the entire study  or parts thereof can be found in Section 12.
13.[ADDRESS_997346] prior to her entry  into the study  (i.e. before any  
examinations and procedures associated with the selection for the stud y are performed or an y 
study -specific data is recorded on study -specific forms).
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 75of 119
The investigator will also mention that written approval of the IRB/IEC has been obtained.
Each subject will be informed about the following aspects of premature withdrawal:
Each subject has the right to withdraw from th e study  at any  time without any  
disadvantage and without having to provide reasons for this decision.  
The subject’s consent covers end -of-study  examinations as specified in the visit 
description described in Sections 6.4and 9.1to be conducted after withdrawal of consent.  
The subject’s data that have been collected until the time of withdrawal will be retained 
and statistically  analy zed in accordance with the statistical anal ysis plan. 
Subject -specific data on the basis of material obtained before withdrawal may  be 
generated after withdrawal (e .g. image reading, analy sis of biological specimen such as 
blood, urine or tissues); these data would also be retained and statisticall y analyzed in 
accordance with the statistical anal ysis plan.  The subject has the right to object to the 
generation and p rocessing of this post -withdrawal data. The subject’s oral objection may  
be documented in the subject’s source data.
Each subject will have ample time and opportunity  to ask questions.
Only  if the subject voluntarily  agrees to sign the informed conse nt for m and has done so, may  
she enter the stud y.  Additionally , the investigator will personally  sign and date the form.  The 
subject will receive a copy of the signed and dated form.
The signed informed consent statement is to remain in the investigator site file or, if locall y 
required, in the patient’s note/file of the medical institution.
In the event that informed consent is obtained on the date that baseline study procedures are 
performed, the study  record or subject´s clinical record must clearl y show tha t informed 
consent was obtained prior to these procedures.
The informed consent form and any other written information provided to subjects will be 
revised whenever important new information becomes available that may  be relevant to the 
subject’s consent, or there is an amendment to the protocol that necessitates a change to the 
content of the subject information and / or the written informed consent form.  The 
investigator will inform the subject of changes in a timely  manner and will ask the subject to 
confirm her participation in the study  by [CONTACT_23667].  Any  
revised written informed consent form and written information must receive the IEC/I RB`s 
approval / favorable opi[INVESTIGATOR_19349].
13.[ADDRESS_997347] s, such as for 
submission to government regulatory  authorities or disclosure to other investigators.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 76of [ADDRESS_997348] free to utilize study  data derived from his/her 
center for scientific purposes, must obtain written consent of the sponsor on the intended 
publication manuscript before its submission.  To this end, the investigator must send a draft 
of the publ ication manuscript to the sponsor within a time period specified in the contract.  
The sponsor will review the manuscript promptly  and will discuss its content with the 
investigator to reach a mutually  agreeable final manuscript.  
13.6 Compensation for health damage of subjects / insurance
The sponsor maintains clinical trial insurance coverage for this study  in accordance with the 
laws and regulations of the country  in which the study  is performed.
13.[ADDRESS_997349] will be kept confidential and, to the extent permitted by  [CONTACT_3999]/or regulations, will not be made publicly available.
Subject names will not be supplied to the sponsor.  Only the subject number will be recorded 
in the CRF, and if the subject name [CONTACT_9005] (e.g. pathologist report), it 
must be obliterated before a cop y of the document is supplied to the sponsor.  Study findings 
stored on a computer will be stored in accordance with local data protection laws.  As part of 
the informed consent process, the subjects will be informed in writing that representatives of 
the sponsor, IEC/I RB, or regulatory  authorities may  inspect their medical records to verify  the 
information collected, and that all personal information made available for inspection will be 
handled in strictest confidence and in accordance with local data protection laws.
If the results of the stud y are published, the subject’s identity  will remain confidential.
The investigator will maintain a list to enable subjects t o be identified.
14. Reference list 
This section was changed in Amendment 1, see Section [IP_ADDRESS].
1.McNicholas C, Swor E, Wan L , Peipert JF. Prolonged use of the etonogestrel implant and 
levonorgestrel intrauterine device: 2 years bey ond Food and Drug Administration -
approved duration. Am J Obstet Gy necol. 2017 Jan 29[Epub ahead of print].
2.Rowe P, Farley  T, Peregoudov A, Pi[INVESTIGATOR_25192] G, Boccard S, Landoulsi S , Meirik O; IUD 
Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of 
Research; Development and Research Training in Human Reproduction. Safet y and 
efficacy  in parous women of a 52 -mg levonorgestrel -
medicated intrauterine device: a 7-
year randomized comparative study  with the TCu380A. Contraception. 2016 
Jun;93(6):498 -506. doi: 10.1016/j.contraception.2016.02.024. Epub 2016 Feb 23.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 77of 119
3.Sivin I , Stern J, Coutinho E, Mattos CER, El Mahgoub S, Diaz S et al. Prolonged 
intrauterine contraception: a se ven-year randomized study  of the levonorgestrel 20 
mcg/day  (LNG 20) and the Copper T380 Ag IUDS. Contraception 1991;44:473-80.
4.Hidalgo MM1, Hidalgo -Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes 
L. Serum levonorgestrel levels and endometrial thi ckness during extended use of the 
levonorgestrel -releasing intrauterine s ystem. Contraception. 2009 Jul;80(1):84- 9. doi: 
10.1016/j.contraception.2009.01.004. Epub 2009 Feb 27.
5.Andersson K, Odlind V, Ry bo G. Levonorgestrel -releasing and copper -releasing (Nova T) 
IUDs during five years of use: a randomized comparative trial. Contraception. 
1994;49(1):56 -72. PubMed PMI D: 8137626.
6.A46796 Phase 2 CSR.  Multi -center, open, randomized, dose finding phase II stud y to 
investigate for a maximum of three years ultra l ow dose levonorgestrel contraceptive 
intrauterine s ystems (LCS) releasing in vitro 12 µg/24 h and 16 µg/24h of levonorgestrel 
compared to MIRENA in nulliparous and parous women in need of contraception.  Bayer 
HealthCare AG, [ADDRESS_997350] udy No. [ZIP_CODE] (alias 308901), version 
2.0.  14 SEP 2011.
7.B073 Clinical Study  Report. Serum levonorgestrel concentration during 78 month use of 
LNG IUD. Schering. 22 Nov 1991.
8.B078 Clinical Study  Report. Five -year clinical performance of the new formulation of the 
levonorgestrel intrauterine y stem and serum levonorgestrel concentration with the new 
formulation compared to that with the original one. L eiras 18 JAN 1999.
9.PH-[ZIP_CODE] Phase 3 CSR. Multi -center, open -label, randomized study  to assess the safet y 
and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra 
low dose levonorgestrel contraceptive intrauterine sy stems (L CS) for a maximum of 3 
years in women 18 to 35 y ears of age and an extension phase of the 16 µg/24 h dose gro up 
(LCS16 arm) up to 5 y ears. Bay er HealthCare AG, [ZIP_CODE] [LOCATION_015] . Study  
No. [ZIP_CODE] (alias 310442), version 2.0, 06 Aug 2015.
10. Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with 
levonorgestrel -releasing and copper intrauteri ne devices in the European Active 
Surveillance Study  on Intrauterine Devices. Contraception. 2015 Apr;91(4):274 -9.
11.A52238 Phase 3 CSR. Multi -center, open -label, randomized study  to assess the safet y and 
contraceptive efficacy  of two doses (in vitro 12 μg/2 4 h and 16 μg/24 h) of the ultra low 
dose levonorgestrel contraceptive intrauterine s ystems (L CS) for a maximum of 3 y ears in 
women 18 to 35 y ears of age and an extension phase of the 16 μg/24 h dose group (L CS16 
arm) up to 5 years. Bayer HealthCare AG, 51 368 [LOCATION_015] . Study  No. [ZIP_CODE] 
(alias 310442), version 2.0, 06 Aug 2015.
12.Heikinheimo O, Inki P, Schmelter T, Gemzell -Danielsson K. Bleeding pattern and user 
satisfaction in second consecutive levonorgestrel -releasing intrauterine s ystem users: 
results of a prospective 5- year stud y. Hum Reprod. 2014 Jun;29(6):1182 -8. doi: 
10.1093/humrep/deu063. Epub 2014 Mar 28 .
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 78of [ADDRESS_997351];86(4):345- 9. doi: 10.1016/j.contraception.2012.01.015. Epub 
2012 Mar 6.
15. Protocol amendments
15.1 Amendment 1 –dated 20SEP [ADDRESS_997352] global amendment. The following is an overview of the changes 
made to the original Protocol Version 1.0.
This amendment describes the assessments and statistical anal yses needed to support a
submission with 6- year efficacy  and safet y data to extend the duration of Mirena use to up to 
6 years.  In addition, protocol has been revised in order to consider the comments and 
feedback from the FDA ( received 31 JAN 2017 and 12 JUL  2017). Also, minor edits and 
clarifications that were not previously  identified in the original protocol were included in this 
amendment.
15.1.1 Overview of the changes to the study
[IP_ADDRESS] Modification 1: Addition of the 6 -year analysis and the required
assessment sneeded for the analyses at Year 6
Rationale : To be able to submit the data to the FDA after [ADDRESS_997353] of protocol sections affected b y this modification:
Section 5 Study  design
Section 9.1 Tabular schedule of evaluations
Section 9.2.5 12- month visit –Visit 4 (End of Year 6 of Mirena use)
Section 9.7.[ADDRESS_997354] satisfaction with Mirena
Section 10.2 Analy sis sets
Section [IP_ADDRESS].1 Primary efficacy  variable
Section [IP_ADDRESS] Analy sis of the primary  variable
Section [IP_ADDRESS].2 Categorized menstrual blood loss (MBL) (<80ml / 30 day s)
Section 10.5 Planned interim analy ses
[IP_ADDRESS] Modification 2: Guidance about number of 34 -
or 35-year old women 
to be included into the screening period
Rationale :In order to ensure sufficient sample size for the final Pearl Index analy sis (i.e. 
targeted 350 women aged 33 y ears or younger at baseline visit / aged 36 years or younger at 
the end of Year 8), screening of women who are [ADDRESS_997355] completed the baseline visit .
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 79of [ADDRESS_997356] of protocol sections affected b y this modification:
Section 6 Study  population   
[IP_ADDRESS] Modification 3: Information on i nclusion range for laboratory values
added
Rationale : As requested by  [CONTACT_730147] b y this modification:
Section 6.2 Exclusion criteria
Section [IP_ADDRESS] Safety  laboratory  tests
[IP_ADDRESS] Modification 4: Rev ision of the criteria for mandatory withdrawal 
from the study
Rationale : Subject must be withdrawn if stroke, my
ocardial infarction, uterine malignancy  
and cervical malignancy  occur during the stu dy; requested by  [CONTACT_1622].
List of protocol sections affected by [CONTACT_8994]:
Section 6.4.1 Withdrawal
[IP_ADDRESS] Modification 5: Clarification on counting of pregnancies with the 
estimated date of conception within 7 days after the end of Mirena 
treatment for the Pearl Index calculation 
Rationale : As requested by  [CONTACT_730147] b y this modification:
Sectio n [IP_ADDRESS] Pregnancies occ urring after the end of study  treatment
Section [IP_ADDRESS] Analy sis of the primary  variable .
[IP_ADDRESS] Modification 6: Clarification of the post -treatment pregnancy tracking 
process (PTPT)
Rationale : To better distinguish the PTPT process-related data from the post -treatment 
pregnancy  data collected at the [ADDRESS_997357] of protocol sections affected b y this modification:
Section 9.2.10 3- week follow -up call (EOS)
Sectio n 9.2.[ADDRESS_997358] -study  pregnancies
Section 9.2.[ADDRESS_997359] for return- to-fertility
Section [IP_ADDRESS] Pregnancies during the stud y
Section [IP_ADDRESS] Pregnancies occ urring after the end of study  treatment
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 80of 119
[IP_ADDRESS] Modification 7: Clarification and correction of terms used in the 
definition
sfor calculation of crude exposure time
Rationale : As requested by  [CONTACT_1622].
List of protocol sections affected b ythis modification:
Section [IP_ADDRESS] Analy sis of the primary  variable
[IP_ADDRESS] Modification 8: Clarification of excluded exposure time due to back - up 
contracep tion use
Rationale : As requested by  [CONTACT_1622].
List of protocol sections affected b y this modification:
Section [IP_ADDRESS] Analy sis of the primary  variable .
[IP_ADDRESS] Modification 9: Addition of sensitivity analysis for PI
[CONTACT_104504] : As requested by  [CONTACT_1622].
List of protocol sections affected b y this modification:
Section [IP_ADDRESS] Analy sis of the primary  variable .
[IP_ADDRESS] Modification 10
: Addition of a reference to the statistical analysis plan 
regarding handling of partial or missing data
Rationale : To provide guidance on how to handle missing or partial data , i.e. missi ng 
bleeding intensities to be recorded by  [CONTACT_730148]/or missing and partial data 
on sanitary  products to be collected b y the subject .
List of protocol sections affected b y this modification:
Secti on [IP_ADDRESS].1
Menstrual blood loss
Section [IP_ADDRESS].2 Bleeding pattern .
[IP_ADDRESS] Modification 11: Clarification of the definition of clinical change in 
bleeding profile regarding HMB and ofthe proportion of subjects with 
clinical change in bleeding profile regarding HM B
Rationale : To clarify  when clinical change in bleeding profile regarding HMB will be 
concluded, to add the stricter success criterion (i.e. upper confidence limit ≤ 35%) for this 
endpoint as requested b y FDA and to provide more details on the nominator and 
denominators used to calculate the proportion of subjects with clinical change in bleeding 
profile regarding HMB. 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 81of [ADDRESS_997360] of protocol sections affected b y this modification:
Section [IP_ADDRESS].2 Categorized menstrual blood loss (MBL) (<80ml / 30 day s).
[IP_ADDRESS] Modification 12: Change in exclusion criterion about simultaneous 
participation in other trials 
Rationale : Study  subjects can participate in observati on trials while in the study . To allow 
this, the wording in exclusion criterion #[ADDRESS_997361] of protocol sections affected b y this modification:
Section 6.2 Exclusion criteria .
[IP_ADDRESS] Modification 13: Withdrawal from study if heavy menstrual bleeding 
returns
Rationale : Investigator should consider if a subject should be withdrawn from the study  in 
case heav y menstrual bleeding returns during the study
Listof protocol sections affected b y this modification:
Section 6.4.1 Withdrawal
[IP_ADDRESS] Modification 14: Reference to a local laboratory removed from the text.
Rationale : Mistake in the original protocol.
List of protocol sections affected b y this modification:
Section [IP_ADDRESS] Test for chlamy dia.
[IP_ADDRESS] Modification 15: Revised terminology of the adverse events to be 
included in the main safety analysis, and correction of the list of other 
safety variables.
Rationale : To ensure consistent wording across different studies, terminology  of adverse 
events to be included in th e main safet y analysis was revised from “post -baseline” to 
“treatment -emergent”. It was a m istake in the original protocol in the list of other safet y 
variables. 
List of protocol sections affected b y this modification:
Section [IP_ADDRESS] Safety  variables
Section [IP_ADDRESS] Analy sis of safet y variables .
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 82of 119
[IP_ADDRESS] Modification 16: Improved instructions for collection of used sanitary 
products 
Rationale :  To provide more guidance to the investigators and site personnel.
List of protocol sections affe cted b y this modification:
Section 9.1 Tabular schedule of evaluations .
[IP_ADDRESS] Modification 17: Correction of the in cervical smear instructions at 
EOT visit
Rationale :  Mistake in the original protocol.
List of protocol sections affected b y this modification:
Section 9.2.9 36 -month visit, EOT – Visit 8 (End of Year 8 of Mirena use)
[IP_ADDRESS] Modification 18: Change in the SOPs to be followed for assessing 
important deviations
Rationale :  CRO’s 
SOPs will be used for the assessment of protocol deviations
List of protocol sections affected b y this modification:
Section 10.2 Analy sis sets
[IP_ADDRESS] Modification 19: Definition of a bleeding/spotting epi[INVESTIGATOR_730099] :  Correction of the bleeding intensity  codes for bleeding/spotting epi[INVESTIGATOR_730100] b y this modification:
Section [IP_ADDRESS] Uterine bleeding
Section [IP_ADDRESS].2 Bleeding pattern
[IP_ADDRESS] Modification 20
: Update of the background information
Rationale : To include recently  published data about extended use of Mirena.
List of protocol sections affected b y this modification:
Section 3. I ntroduction 
Section [ADDRESS_997362]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 83of 119
[IP_ADDRESS] Modification 21: Information on post -study contraception
Rationale : To inform the subject about the options for contraception after the study  in order 
to decrease the chances for unplanned pregnancies after t he stud y.
List of protocol section affected b y this modification:
Section 9.2.8 30- month visit –Visit 7
[IP_ADDRESS] Modification 22: Mandatory TVU Sif removal threads are not found
Rationale : To ensure that Mirena is in the appropriate intrauterine location and to exclude 
expulsion or perforation.
List of protocol section affected b y this modification:
Section [IP_ADDRESS] Presence of Mirena removal threads
[IP_ADDRESS] Modification 2
3: Clarifications
Rationale : Textual editing for clarit yand consistency  between sections, administrative 
changes and corrections of mistakes
.
List of protocol sections affected b y this modification:
Section 2. Sy nopsis
Section 9.2 Visit description
Section 11.1 Data re cording
Section 13.1 I nvestigators and other study  personnel .
[IP_ADDRESS] Modification 24: Instructions r egarding bleeding irregularities detected 
in women using Mirena for contraception only
Rationale : As per FDA request
List of protocol sections affected b y this modification:
Section 9.1 Tabular schedule of evaluations
Section 9.2 Visit description
[IP_ADDRESS]
Modification 25: Collection of age at B aseline visit (Visit 2)
Rationale : Age at baseline will be needed for the statistical analy sis.As baseline might be up 
to [ADDRESS_997363] of protocol sections affected by [CONTACT_8994]:
Section 9.1 Tabular schedule of evaluations
Section 9.2.3 Basel ine 
–Visit 2
Section 9.3.1 Demographic
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 84of 119
Section 10.2 Analy sis sets
Section 9.2 Visit description
[IP_ADDRESS] Modification 26: Revision of the definition for start of treatment period 
for the primary variable
A new term ‘extension treatment period’ is introduced. This period starts at Day  1 of Year 6 
of Mirena. Variables collected on an ongoing basis will primarily  be anal yzed for the 
‘extension treatment period’ starting at Day  1 of Year 6 of Mirena use, i.e., data collected 
between the baseline visit and Day  1 of Year 6 of Mirena use will be excluded.
Rationale: This enables the calculation of the Pearl I ndex for the period of extended use of 
Mirena bey ond the five years.  Change was requested by  [CONTACT_1622].
List of protocol sections affected b y this modification:
Section 10.3 Variables and planned statistical analy ses
Section [IP_ADDRESS].1 Primary efficacy  variable
Section [IP_ADDRESS] Safety  variables
Section [IP_ADDRESS] Analy sis of the primary  variable
Section [IP_ADDRESS] Analy sis of safet y variables
Section [IP_ADDRESS].2 Bleeding pattern
15.1.2 Changes to the protocol text
In the sections on changes to the protocol text, all protocol sections affected by  [CONTACT_471452]; the sequence of the sections follows the structure of the original
protocol. As applicable, changes to the protocol text are highlighted as follows:
1.Addition of a whole new portion Brief identification of the new portion
2.Removal of a whole portion Complete display  of the removed portion, formatted 
as crossed out
3.Editing of an existing portion Comparative presentation of “old text” versus “new 
text”, with “old text” referring to the most recent 
previous protocol version. Deletions are crossed out
in the “old text”. Additions are underlined in the 
“new text”. 
Tables / figures The term “amended” is added to the caption.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 85of 119
Terminological changes Brief specification of the terminological change
Thus, in this section, a terminological change (e.g. 
“period” versus “epoch”) is defined only  once, 
without display ing “old text” versus “new text” for 
each appearance.
Correction of t ypos or omissions are not highlighted in this section.
[IP_ADDRESS] Section 2. Synopsis
This section was changed as a result of Modification [IP_ADDRESS]
Old text :
Short title Mirena Extension study
New text :
Short title Mirena Extended Trial
[IP_ADDRESS] Section 3. Introduction 
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
[…]
Two controlled contraceptive efficacy  studies on extended use bey ond the indicated 5 y ears 
up to 7 y ears (1, 2) have been published. In the recently  published study  by [CONTACT_730105] 2016, 
the overall pregnancy  rate of the TCu380A was significantly  higher than that of the L NG 
IUD: at the end of the seventh y ear the cumulative rate was 2.45 (standard error [SE] 0.44) 
per 100 for the TCu380A and 0.53 (SE 0.21) per 100 for the LNG IUD.
[…]
New text :
[…]
Three contraceptive efficacy  studies on extended use bey ond the indicated 5 years up to 7 
years (1, 2, 3 ) have been published. I n a comparative study  the effectiveness of the 
contraceptive implant and the 52 -mg hormonal intrauterine device in women using the 
method for 2 years beyond the approved duration was evaluated ( 1). Among [ADDRESS_997364] been 
reported. The failure rate in the sixth y ear of use of the LNG IUS is calculated as 0.25 
(95% CI, 0.04 -1.42) per 100 woman- years; failure rate during the seve nth y ear is 0.43 (95% 
CI 0.08 -2.39) per 100 woman- years.In the recently published stud y by [CONTACT_730105] 2016 (2), 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 86of [ADDRESS_997365] G 
IUD: at the end of the seventh y ear the cumulative rate was 2.45 (standard error [SE] 0.44) 
per 100 for the TCu380A and 0.53 (SE 0.21) per 100 for the LNG IUD.
[…]
[IP_ADDRESS] Section 5 Study design
This section was cha nged as a result of Modification [IP_ADDRESS].
Old text :
[…]
An anal ysis of the efficacy  and safet y data will be conducted after all subjects have either 
completed 7years of tr eatment, or prematurel y terminated their study  participation before this 
time point. 
[…]
New text :
[…]
An anal ysis of the efficacy  and saf ety data will be conducted after all subjects have either 
complete d 6years of treatment (i.e. completed 1 year in the stud y), or prematurel y terminated 
their study  participation before this time point. Another  anal ysis of the efficacy  and safet y 
data wil l be conducted after all subjects have either completed 7 years of treatment (i.e. 
completed 2 years in the study ), or prematurely  terminated their study  participation before this 
time point.
[…]
[IP_ADDRESS] Section 6 Study population
This section was changed as a result of Modific ation [IP_ADDRESS].
New text –addition of footnote 1:
[…]
The study  will include fertile age women (18 to 35 y ears at the time of the screening visit ) 
currentl y using a Mirena for contraception or for contraception and heav y menstrual bleeding 
and who have had the Mirena in situ for at least 4 y ears and 6 months but no longer than 5 
years and are willing to continue its use for contraception or contraception and heav y 
menstrual bleeding for up to 8 y earsintotal. About 90% of the women included will be 18 to 
32 (inclusive) years of age at screening (visit 1)1.
Text for Footnote 1: Screening of women who are [ADDRESS_997366] completed the baseline visit, for details see Section 10.4 .
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 87of 119
[IP_ADDRESS] Section 6.2 Exclusion criteria
This section was changed as a result of Modificat ion [IP_ADDRESS] and [IP_ADDRESS].
Old text :
[…]
21. Laboratory  values outside inclusion range before baseline and considered clinically  
relevant.
22. Simultaneous participation in another clinical trial. Participation in another clinical 
trial prior to study  entry  that might have an impact on the study  objectives, at the 
discretion of the investigator.
New text :
[…]
21. Laboratory  values outside inclusion range before baseline and considered clinically  
relevan t (see Section [IP_ADDRESS]) .
22. Simultaneous participation in another clini cal study  with investigational medicinal 
product(s). Participation in another clinica l trial prior to study  entry that might have an 
impact on the study  objectives, at the discretion of the investigator.
[…]
[IP_ADDRESS] Section 6.4.1 Withdrawal
This section was changed as a result of Modificat ion [IP_ADDRESS] and [IP_ADDRESS].
Old text :
[…]
Subjects must be withdrawn from the stud y if an y of the following occurs:
[…]
Acute pelvic inflammatory  disease (PID) not responding to treatment
Genital malignancy
Liver tumor (benign or malignant)
Allergic reaction to the study  medication or an y of its components
If, in the investigator’s opi[INVESTIGATOR_1649], continuation of the study  would be harmful to the 
subject’s well -being
[…]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 88of 119
Subjects may be withdrawn from the stud y if an y of the following occurs:
[…]
Marked increase of blood pressure
Severe arterial disease such as stro ke or m yocardial infarction
Uterine or cervical malignancy
Jaundice
[…]
Should the subject, during the course of the study , develop conditions which would 
have prevented her entry  into the study  according to the exclusion criteria, she must be 
withdrawn immediatel y if safet y is concerned. In other cases, the investigator will 
decide if there is a conflict with study  objectives.
At the specific request of the sponsor and in liaison with the investigator (e.g. obvious 
non-compliance, safet y concerns).
The r easons for an y withdrawal are to be fully  documented on the eCRF.
[…]
New text :
[…]
Subjects 
must be withdrawn from the stud y if an y of the following occurs:
[…]
Acute pelvic inflammatory  disease (PID) not responding to treatment
Genital malignancy (e.g., uterine or cervical malignancy )
Severe arterial disease such as stroke or m yocardial infarction
Liver tumor (benign or malignant)
Allergic reaction to the study  medication or an y of its components
If, in the investigator’s opi[INVESTIGATOR_1649], continuation of the stu dy would be harmful to the 
subject’s well -being
Should the subject, during the course of the study , develop conditions which would 
have prevented her entry  into the study  according to the exclusion criteria, she must be 
withdrawn immediatel y if safet y is c oncerned. In other cases, the investigator will 
decide if there is a conflict with study  objectives.
[…]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 89of 119
Subjects may be withdrawn from the stud y if an y of the following occurs:
[…]
Marked increase of blood pressure
Jaundice
[…]
At the specific request of the sponsor and in liaison with the investigator (e.g. obvious 
non-compliance, safet y concerns).
Return of heav y menstrual bleeding, if it affects the subject’s well
-being, based on the 
investigator’s clinical judgment
The reasons for an y withdrawal are to be fully  documented on the eCRF.
[…]
[IP_ADDRESS] Section 9.1 Tabular schedule of evaluations
This section was changed as a result of Modification [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], and
[IP_ADDRESS].
Old text :
Integrated Clinical Study Protoco l
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 90of 119
Table 9 –1 Schedule of activities and evaluations
PeriodScreening
(0 to 6 mo)Treatment Period 
(3 years; Mirena y ears 6 thru 8)Pregnancy  Follow -up 
(up to 12 mo)
Visit
Prescreening 
contact 
(optional)
Screening 
BaselineEOTaEOS
All 
subjects3-mo 
contact
b12-mo 
contact
c
Visit number / 1 2 3 4 5 6 7 8   
Timingwithin 
60 day sDay 1 6 mo
±14 d12 mo
±14 d18 mo
±14 d24 mo
±14 d30 mo
±14 d36 mo
-14 d3 wks 
after 
EOT
-3 d3 mo 
after 
EOT
-7 d/+14 
d12 mo 
after 
EOT
+7 d
Duration of Mirena use4 y 6 mo 
to 5 
years5 yearsd6 years 7 years 8 years
[…]
Demography X
[…]
Physical examination X X X
Vital signs, body weight X+height X X
Gynecological exam. incl. breast palpation X X X
[…]
Urine pregnancy test gX X X X X X X X X
[…]
Dispense home pregnancy test kits X X X X X X
[…]
Subject satisfaction with Mirena X X X
Footnote explanations:
cFor subjects that prematurely discontinued treatment due to ‘W ish for pregnancy’ will be contact[INVESTIGATOR_530]. If a subject was not pregnant at [ADDRESS_997367] was “Lost to Follow -up” at [ADDRESS_997368] is 
required. See also Section 9.4.1.
[…]
gIn addition to t he urine pregnancy tests performed by [CONTACT_420406], subjects will be given home urine pregnancy tests to be used whenever a 
Integrated Clinical Study Protoco l
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 91of [ADDRESS_997369].
Integrated Clinical Study Protoco l
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 92of 119
New text :
Table 9 –1 Schedule of activities and evaluations –amended 
PeriodScreening
(0 to 6 mo)Treatment Period 
(3 years; Mirena y ears 6 thru 8)Pregnancy  Follow -up 
(up to 12 mo)
Visit
Prescreening 
contact 
(optional)
Screening 
BaselineEOTaEOS
All 
subjects3-mo 
contact
b12-mo 
contact
c
Visit number / 1 2 3 4 5 6 7 8   
Timingwithin 
60 day sDay 1 6 mo
±14 d12 mo
±14 d18 mo
±14 d24 mo
±14 d30 mo
±14 d36 mo
-14 d3 wks 
after 
EOT
-3 d3 mo 
after 
EOT
-7 d/+14 
d12 mo 
after 
EOT
+7 d
Duration of Mirena use4 y 6 mo 
to 5 
years5 yearsd 6 years 7 years 8 years
[…]
Demography X
Age at baseline X
[…]
Physical examination X X X X
Vital signs, body weight X+height X X X
Gynecological exam. incl. breast palpation X X X X
[…]
Urine pregnancy test gX X X X X X X X X g
[…]
Dispense home pregnancy test kits X X X X X X X
[…]
Subject satisfaction with Mirena X X X X
[…]
Footnote explanations:
cSubjects that prematurely discontinued treatment due to ‘W ish for pregnancy’ will be contact[INVESTIGATOR_530]. If a subject was not pregnant at [ADDRESS_997370] and no 
Integrated Clinical Study Protoco l
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 93of [ADDRESS_997371] was “Lost to Follow -up” at [ADDRESS_997372] is 
required. See also Section 9.4.1.
[…]
g In addition to the urine pregnancy tests performed by [CONTACT_420406], subjects will be given home urine pregnancy tests to be used whenever a 
pregnancy is suspected.  Subjects must contact [CONTACT_730149] a pregnancy test is positive.  Home pregnancy test is to be done on the day of 
the [ADDRESS_997373].
[…]
d=day, EOS=end of study, EOT=end of treatment, mo=month, PK=pharmacokinetics, wks=weeks, y=year
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 94of 119
Old text :
[…]
Subjects in the HMB subgroup (i.e. all women who had the Mirena inserted for contraception 
and heav y menstrual bleeding) will collect their used sanitary products (provided by [CONTACT_3211]) 
during [ADDRESS_997374] to be 
returned to the stud y site at time points given in Table 9
-2.
[…]
New text :
[…]
Subjects in the HMB subgroup (i.e. all women who had the Mirena inserted for contraception 
and heav y menstrual bleeding) will collect their used sanitary products (provided by  [CONTACT_3211]) 
during [ADDRESS_997375] to be 
returned to the stud y site as instructed in Section 9.4.2 and display edin Table 9 -
2.
[…]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 95of 119
Old text :
[…]
Table 9–2 Schedule of activities needed for the MBL evaluations
HMB subgroup only – additional activities for baseline (BL) visit and treatment period
Period
ScreeningTreatment Period (Mirena y ears 6 thru 8)
30 day s after 
baseline 
visit30 day s prior 
tovisit 430 day s prior 
tovisit 630 day s prior 
toEOT
Visit / visit 
number
Baseline (BL) 
Visit 2
Return
Return
Visit 3
Return 
Visit 4
Visit 5
Return
Visit 6
Visit 7
Return
EOT 
Visit 8
Timing2 
weeks2 
weeks 
after 
BL30 
days 
after 
BL6 mo
±2 
weeks2 
weeks 
before 
V412 mo 
±2 
weeks 18 mo
±2 
weeks2 
weeks 
before 
V624 mo
±2 
weeks30 mo
±2 
weeks2 
weeks 
before 
EOT36 mo
2 
week
s
Dispense 
alkaline 
hematin kit X X X X
Collection of 
used towels 
and tampons       
Return of 
used towels 
and tamponsX X X X X X X X
Note:   Return required only if sanitary protection has been used in the time periods indicated.
Note:  For all other activities and evaluations, please refer to Table 9 1. 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 96of 119
New text :
[…]
For subjects who have the Mirena inserted for contraception onl y: if bleeding irregularities 
develop during prolonged treatment, appropriate diagnostic measures should be taken by  [CONTACT_730112] .
Table 9 –2 Schedule of activities needed for the MB L evaluations –amended 
HMB subgroup only – additional activities for baseline (BL) visit and treatment period. For all other 
activiti es and evaluations, see Table 9 -1.
Period
ScreeningTreatment Period (Mirena y ears 6 thru 8)
Collection 
time30 day s after 
baseline 
visit,
Study  Days 
2 to 31 
(inclusive)Study  Days 
322 to 351 
(inclusive)
before Visit 4Study  Days 
687 to 716 
(inclusive)
before Visit 6Study  Days 
1052 to 1081 
(inclusive)
before EOT 
visit
Visit / visit 
number
Baseline (BL) 
Visit 2
Return
Return
Visit 3
Return 
Visit 4
Visit 5
Return
Visit 6
Visit 7
Return
EOT 
Visit 8
Dispense 
alkaline 
hematin kit X X X X
Collection of 
used sanitary 
products       
Return of 
used sanitary 
productsaX X X X X X X X
Study Day 1 = Day of the baseline visit (Visit 2)
a Used sanitary products should not be kept at home longer than [ADDRESS_997376] been used in the time periods indicated.
[IP_ADDRESS] Section 9.2 Visit description
This section was changed as a result of Modification [IP_ADDRESS] 3.
Old text :
The timing of the visits is based on the date of the baseline visit.  Treatment period starts at 
the baseline visit (Visit 2, defined as Day  1).
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 97of 119
New text :
The timing of the visits is based on the date of the baseline visit.  Treatment period starts at 
the baseline visit (Visit 2, defined as Study Day 1).
[IP_ADDRESS] Section 9.2.3 Basel ine – Visit 2
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
The following procedures and assessments will be done:
Re-check inclusion/exclusion criteria (Sections 6.1and 6.2)
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
[…]
New text:
The following procedures and assessments will be 
done:
Re-check inclusion/exclusion criteria (Sections 6.1and 6.2)
Age at baseline (Section 9.3.1)
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
[…]
[IP_ADDRESS] Section 9.2.5 12-month visit – Visit 4 (End of Year 6 of Mirena use)
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
The following procedures and assessments will be done:
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform urine pregnancy test (Section [IP_ADDRESS])
Perform safet y
laboratory  test and urinal ysis (Section [IP_ADDRESS])
Blood sample for PK (Note: subjects r andomized to this visit ) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section
8.1)
AEs (Section 9.6.1)
Continuing need for contraception (Section 9.7.1)
Dispense home pregnancy  kits with instructions ( Section
[IP_ADDRESS] )
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 98of 119
New text :
The following procedures and assessments will be done:
Assess vital signs and weight (Section [IP_ADDRESS])
Perform general ph ysical examination (Section [IP_ADDRESS] )
Perform gy necological examination (with breast palpation ; Section [IP_ADDRESS]
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Perform urine pregnancy test (Section [IP_ADDRESS])
Perform safet y
laboratory  test and urinal ysis (Section [IP_ADDRESS] )
Blood sample for PK (Note: subjects randomized to this visit
) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section
8.1)
AEs (Section 9.6.1)
Continuing need for contra ception (Section 9.7.1)
Dispense home pregnancy  kits with instructions ( Section
[IP_ADDRESS])
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception.
Subject satisfaction with Mirena (Section 9.7.4).
[IP_ADDRESS] Section 9.2.8 30- month visit – Visit 7
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
[…]
Dispense alkaline hematin kit with instructions for subjects in HMB group .
New text :
[…]
Dispense alkaline hematin kit with instructions for subjects in HMB group.
Discuss the contraceptive options available after the study  treatment with the subject (see 
Section 8.2).
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 99of 119
[IP_ADDRESS] Section 9.2.9 36-month visit, EOT – Visit 8 (End of Year 8 of Mirena 
use)
This section was changed as a result of Modifica tion [IP_ADDRESS].
Old text :
The following procedures and asses sments will be done:
[…]
Perform pelvic examination to visualize Mirena rem oval threads (Section [IP_ADDRESS] )
Obtain cervical smear (Section [IP_ADDRESS]).  A cervical smear should be taken at this visit 
or a documented normal result (using the Bethesda sy stem or a corresponding s ystem) 
has to have been obtained within 6 months before the Screening Visit (Visit 1). 
Subjects with ASCUS can be included if they  have a HPV DNA test that, according to 
the stand ards of the local laboratory , is negative for high risk HPV.  A c ervical smear 
may be repeated once if the screening result is abnormal.
Perform urine pregnancy test (Section [IP_ADDRESS] )
Perform safet y laboratory  test and urinal ysis (Section [IP_ADDRESS])
Blood sa mple for PK ( all subjects ) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section
8.1)
AEs (Section 9.6.1)
Continuing need for contraception (Section 9.7.1)
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception.
Collect eDiary  device (Section 9.7.1)
Subject satisfaction with Mirena (Section 9.7.4)
Remove the Mirena (Section 9.7.3)
Complete Mirena removal ease (investigator) and pain (subject) 
assessment
New text :
The following procedures and assessments will be 
done:
Assess v ital signs and weight (Section [IP_ADDRESS])
Perform general ph ysical examination (Section [IP_ADDRESS])
Perform gy necological examination (with breast palpation ; Section [IP_ADDRESS])
Perform pelvic examination to visualize Mirena removal threads (Section [IP_ADDRESS] )
Obtain cervical smear (Section [IP_ADDRESS])
Perform urine pregnancy test (Section 
[IP_ADDRESS])
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 100of 119
Perform safet y laboratory  test and urinal ysis (Section [IP_ADDRESS] )
Blood sample for PK ( allsubjects ) (Section 9.5.1)
Interview for the following:
Concomitant medications (Section
8.1)
AEs (Section 9.6.1)
Continuing need for contraception (Section 
9.7.1)
Dispense home pregnancy kits with instructions (
Section [IP_ADDRESS])
Review completed (monthly ) eDiary, including information on uterine bleeding and 
back -up contraception.
[IP_ADDRESS] Section 9.2.10 3-week follow - up call (EOS)
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
All subjects will be contact[INVESTIGATOR_530] 3 weeks after EOT (i.e. after M irena removal) to collect 
information on an y pregnancy detected shortl y after the end of study treatment.
New text :
All subjects will be contact[INVESTIGATOR_530] 3 weeks after EOT (i.e. after Mirena removal) to collect 
information on an y pregnancy detected shortl y after the end of study  treatment, see Section 
9.4.1 .
[IP_ADDRESS] Section 9.2.[ADDRESS_997377] -study pregnancies
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
Subjects who prematurely discontinued stud y treatment will be contact[CONTACT_730118] “pregnancy ”, “death”, or “withdrawal b y subject” where the 
subject has withdrawn main consent during study  conduct and wishes to stop future contact 
[CONTACT_36362] . For subjects that had withdrawn consent during stud y, but consented to post 
study  participation follow -up, post treatment pregnancy  tracking information is expected.  At 
this time, subjects will be asked if they  have been pregnant after the study  (i.e. after the 3 -
week follow -up call) .
Please see Section 9.4.1.
New text :
Subjects who prematurely discontinued stud y treatment will be contact[CONTACT_730118] “pregnancy ”, “death”, or “withdrawal b y subject” where the 
subject has withdrawn main consent duri ng study  conduct and wishes to stop future contact 
[CONTACT_730150].  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 101of [ADDRESS_997378] been pregnant after the study  (i.e. after the 3 -
week follow -up call). This contact [CONTACT_730119] -Treatment Pregnancy  Tracking (PTPT) 
process , see Section 9.4.1 .
[IP_ADDRESS] Section 9.2.[ADDRESS_997379] for return-to -fertility
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
Subjects that prematurel y discontinued treatment due to ‘Wish for pregnancy’ will be 
contact[CONTACT_730151] 12 months after end of treatment
(EOT, i.e. removal of Mirena). If a subject was not pregnant at [ADDRESS_997380] was “Lost to 
Follow -up” at [ADDRESS_997381] is required . Please see Section 9.4.1.
New text :
Subjects that prematurel y discontinued treatment due to ‘Wish for pregnancy’ will be 
contact[CONTACT_730151] 12 months after end of treatment
(EOT, i.e. removal of Mirena). If a subject was not pregnant at [ADDRESS_997382] was “Lost to 
Follow -up” at [ADDRESS_997383] -
Treatment Pregnancy  Tracking (PTPT) process, see Section 9.4.1 .
[IP_ADDRESS] Section 9.3.1 Demographic
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
Demographic data [e.g. year of birth, age at the screening (Visit 1), race, ethnic group, 
educational level] and other population characteristics including tobacco use and alcohol 
consumption will be collected at time points presented in Table 9
-1.
New text :
Demographic data [e.g. year of birth, age at the screening (Visit 1), age at baseline (Visit 2),
race, ethni c group, educational level] and other population characteristics including tobacco 
useand alcohol consumption will be collected at time points presented in Table 9 -1.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 102of 119
[IP_ADDRESS] Section [IP_ADDRESS] Pregnancies during the study
This section was changed as a result of Mo dification [IP_ADDRESS].
Old text :
The investigator must report to the sponsor an y pregnancy occurring in a study  subject during 
her participation in this stud
y.  This report is to be submitted within the same timeframe as an 
SAE (i.e. no later than 24 hours of having gained knowledge of the event), although a 
pregnancy , per se, is not considered an AE/SAE. 
New text :
The investigator must report to the sponsor a ny pregnancy  occurring in a study  subject during 
her participation in this study  including pregnancies detected at the contact 3 weeks after 
EOT.   This report is to be submitted within the same timeframe as an SAE (i.e. no later than 
24hours of having gai ned knowledge of the event), although a pregnancy , per se, is not 
considered an AE/SAE. 
[IP_ADDRESS] Section [IP_ADDRESS] Pregnancies occ urring after the end of study treatment
This section was changed as a result of Modification [IP_ADDRESS] and [IP_ADDRESS].
Old text :
All pregn ancies detected up to [ADDRESS_997384] be reported to 
the sponsor; all subjects will be instructed to contact [CONTACT_730152] [ADDRESS_997385] occurred during study  treatment, further investigations will be 
conducted, and the pregnancy  should be reported immediately  and will be followed up 
according to the process described above for pregnancies durin g the stud y.
3 weeks after EOT:   All subjects will be contact[INVESTIGATOR_530] [ADDRESS_997386] information 
on any  pregnancy  detected shortly  after the end of study  treatment.
New text :
All pregnancies detected up to [ADDRESS_997387] be reported to 
the sponsor; all subjects will be instructed to contact [CONTACT_730152] [ADDRESS_997388] occurre d during s tudy treatment (i.e. up to 7 day s after EOT) , 
further investigations will be conducted, and the pregnancy  should be reported immediately  
and will be followed up according to the process described above for pregnancies during the 
study . 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 103of 119
[…]
Old text :
Post study  pregnancy  tracking information ,including information on all pregnancies 
identified, must be reported to the sponsor via electronic data collection tool (see 
Section 11.1).  In addition, if the estimated date of conception is suspected to have oc curred 
during stud y treatment, 
the pregnancy  should be reported immediatel y according to the 
process described under section [IP_ADDRESS].
New text :
PTPT information, i.e. data collected at the [ADDRESS_997389] be reported to the sponsor via electronic data 
collection tool (see Section 11.1).  In addition, if the estimated date of conception is suspected 
to have occurred during study  treatment, the pregnancy  should be reported immediat ely 
according to the process described under section 
[IP_ADDRESS].
[…]
[IP_ADDRESS] Sectio
n [IP_ADDRESS] Test for chlamydia
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
[…]
A single repeat test is permissible if the screening results are positive.  If the test result is 
positive, the subject must also be tested for gonorrhea.  Gonorrhea tests must also be 
performed using a highl y accurate test method in a local laboratory that meets the standards of 
GLP.A subject with an active genital infection ma y not be assigned to study treatment until 
the infection has been successfull y treated (see Section 6.2, Exclusion criterion 4).  
[…]
New text :
[…]
A single repeat tes
t is permissible if the screening results are positive.  If the test result is 
positive, the subject must also be tested for gonorrhea.  Gonorrhea tests must also be 
performed using a highl y accurate test method that meets the standards of GLP. A subject 
with an active genital inf ection may  not be assigned to study  treatment until the infection has 
been successfull y treated (see Section 6.2, Exclusion criteri on 4).  
[…]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 104of 119
[IP_ADDRESS] Section [IP_ADDRESS] Safety laboratory tests
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
Only  blood samples analy zed at the central laboratory  will be considered for anal ysis.  The 
name [CONTACT_730156] r the central lab service provider can be found in the documentation 
supplied by  [CONTACT_55899].  The safet y laboratory  tests may  be repeated once d uring the 
screening period if laboratory values are outside the inclusion range and assessed as clinicall y 
relevant.
New text :
Only  blood samples analy zed at the central laboratory  will be considered for anal ysis.  The 
name [CONTACT_730157]  [CONTACT_55899].  For a given laboratory  parameter, the acceptable values for inclusion 
would consist of values within the reference ranges, measured at baseline, as provided in the 
Covance Central Laboratory  Services (CCLS) Manual for Bay er Protocol [ZIP_CODE] (Covance 
Project #: 518179). The safet y lab oratory  tests may  be repeated once during the screening 
period if laboratory  values are outside the inclusion range and assessed as clinically  relevant.
[IP_ADDRESS] Section [IP_ADDRESS] Presence of Mirena removal threads
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
[…]
The investigator will perform pelvic examinations at each stud y visit to verify  the presence of 
the Mirena removal threads in t he appropriate location in 
the cervical os.  At the investigator’s 
discretion,transvaginal ultrasound (TVUS) may beperformed to verify  that the Mirena is in 
the appropriate intrauterine location and to exclude expulsion or perforation.  […]
New text :
[…]
The investigator will perform pelvic examinations at each stud y visit to verify  the presence of 
the Mirena removal threads in the appropriate location in the cervical os. If the presence of 
the removal threads cannot be verified, transvaginal ultrasound ( TVUS) is to be performed to 
verify  that the Mirena is in the appropriate intrauterine location and to exclude expulsion or 
perforation.  […]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 105of 119
[IP_ADDRESS] Section [IP_ADDRESS] Uterine bleeding
This section was changed as a result of Modification [IP_ADDRESS].
Old text
Table 9-3 Uterine bleeding –bleeding intensity definitions
Category Intensity Definition
None None No uterine bleeding
Spotting Spotting Less than associated with normal menstruation relative to the woman’s 
experience, with no need for sanitar y protection except for panty liners
Bleeding Light Less than associated with normal menstruation relative to the woman’s 
experience, with need for sanitary protection
Normal Like normal menstruation relative to the woman’s experience
Heavy More than normal menstruation relative to the woman’s experience
New text:
Table 9 -3 Uterine bleeding –bleeding intensity definitions
Category Intensity Bleeding 
Intensity 
CodeDefinition
None None 1 No uterine bleeding
Spotting Spotting 2 Less than associated with normal menstruation relative to the 
woman’s experience, with no need for sanitar y protection 
except for panty liners
Bleeding Light 3 Less than associated with normal menstruation relative to the 
woman’s experience, with need for sanitar y protection
Normal 4 Like normal menstruation relative to the woman’s experience
Heavy 5 More than normal menstruation relative to the woman’s 
experience
[IP_ADDRESS] Section 9.7.1 eDiary
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
[…]
The use of the eDiary  will be explained in detail in a site manual, and the site personnel will 
train the subject on how to use the device at the baseline visit.  At all the following visits (see
Table 9-1), the eDiary  entries will be checked and documented b y the st udy site personnel for 
completeness.  […]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 106of 119
New text:
[…]
Subject will enter her data daily  into the eDiary .The use of the eDiary  will be explained in 
detail in a site manual, and the site personnel will train the subject on how to use the device at 
the bas eline visit.  At all the following visits (see Table 9-1), the eDiary  entries will be 
checked and documented by  [CONTACT_730139].  […]
[IP_ADDRESS] Section 9.7.[ADDRESS_997390] satisfaction with Mirena
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
At baseline visit, visit 6 and at the end of the treatment (EOT, visit 8) (see also Table 9-1), the 
subject is asked to eva luate her satisfaction with the Mirena on a [ADDRESS_997391] satisfaction will be documented b y the investigator in 
eCRF.
New text :
At baseline visit, visit 4, 6 and at the end of the treatment (EOT, visit 8) (see a lso Table 9-1 ), 
the subject is asked to evaluate her satisfaction with the Mirena on a [ADDRESS_997392] satisfaction will be documented b y the investigator in 
eCRF.
[IP_ADDRESS] Section 10.2 Analysis sets
This section was changed as a result of Modificati on [IP_ADDRESS], [IP_ADDRESS] and [IP_ADDRESS] .
Old text :
The documentation of important deviations and the assignment of subject
sto analy sis sets 
will be performed according to the sponsor’s applicable Standard Operating Procedures 
and/or Instruction Manuals.  
The following statistical anal ysis sets will be defined:
Full analysis set (FAS) : 
All women who completed the baseline vi sit of the study
Primary analysis set Year 7 (PAS year 7) :
All women in the FAS with an age of 34 years or y ounger at baseline visit (i.e., an age of 36 
or younger at end of y ear 7)
Primary analysis set Year 8 (PAS year 8) : 
All women in the FAS with an a ge of 33 years or y ounger at baseline visit (i.e., an age of 36 
or younger at end of y ear 8)
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 107of 119
Safety analysis set (SAF) :
All women who completed the baseline visit of the study , anal yzed for the FAS
The age at baseline (required for PAS year 7 and PAS y ear8) will be approximated as the 
difference between year of baseline visit and y ear of birth recorded at screening visit.   
New text :
The documentation of important deviations and the assignment of subjects to analy sis sets 
will be performed according t o the CRO´s applicable Standard Operating Procedures and/or 
Instruction Manuals.  
The following statistical anal ysis sets will be defined:
Full analysis set (FAS) : 
All women who completed the baseline visit of the study
Primary analysis set Year 6 (PAS year 6) :
All women in the FAS with an age of 35 years or y ounger at baseline visit (i.e., an age of 36 
or younger at end of y ear 6)
Primary analysis set Year 7 (PAS year 7) :
All women in the FAS with an age of 34 years or y ounger at baseline visit (i.e., an age of 36 
or younger at end of y ear 7)
Primary analysis set Year 8 (PAS year 8) : 
All women in the FAS with an age of 33 years or y ounger at baseline visit (i.e., an age of 36 
or younger at end of y ear 8)
Safety analysis set (SAF) :
All women who completed the baseline visit of the study , anal yzed for the FAS
The age at baseline (requir ed for PAS year 6 , PAS y ear 7 and PAS y ear 8) will be used as 
recorded at the baseline visit 2.  
[IP_ADDRESS] Section 10.3 Variables and planned statistical analyses
This section was changed as a result of Modification [IP_ADDRESS].
New text added (no old text) :
In order to allow some flexibility, the baseline visit is planned to take place 14 to 0 day s 
before the end of Year 5 of Mirena use (see Table 9 -1). As a consequence, it is expect ed there 
will be various subjects with that baseline visit taking place prior to the start of ‘extension 
treatment period’, i.e. Day 1 of Year 6 of Mirena use. 
Variables collected on an ongoing basis will primarily  be anal yzed for the ‘extension 
treatment period’ starting at Day  1 of Year 6 of Mirena use, i.e., data collected between the 
baseline visit and Day  1 of Year 6 of Mirena use will be excluded: 
Primary  efficacy  variable, i.e. occurrence of pregnancies (section [IP_ADDRESS]) 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 108of 119
Main safet y variable, i.e . adverse events (section [IP_ADDRESS].1) 
Uterine bleeding / bleeding pattern (section [IP_ADDRESS].2) 
Variables collected at pre -specified visits/timeframes only  will be analy zed per visit (unless 
otherwise stated): 
Secondary  efficacy  variable, i.e. menstrual blood loss (section [IP_ADDRESS]) 
Other safety  variables, not listed above (section [IP_ADDRESS]) 
Other variables (section [IP_ADDRESS]) 
More details will be provided in the statistical analysis plan. 
[IP_ADDRESS] Section [IP_ADDRESS].1 Primary efficacy variable
This section was changed as a result of Modification s [IP_ADDRESS] and [IP_ADDRESS].
Old text :
The primary  efficacy  variable is the occurrence of pregnancy  within y ears 6 thru 8 of Mirena 
use.However, for t he analy sis after 7 y ears, the primary  efficacy  variable is the occurrenc e of 
pregnancy  within y ears 6 thru 7 of Mirena use. 
The PI  [INVESTIGATOR_730101] 100 woman y ears. The following PI s will 
be calculated:
'Two yearsPI (sixth & seventh y ear)', PI [INVESTIGATOR_730087], i. e., number of pregnancies that occurred during the sixth and seventh y ear 
of treatment divided b y time the women were under risk of getting pregnant in the 
sixth and seventh y ear of treatment.
'Three yearsPI (sixth, seventh & eighth y ear)', PI [INVESTIGATOR_730088], seventh and 
eighth year of treatment, i.e., number of pregnancies that occurred during the sixth, 
seventh and eighth year of treatment divided b y time the women were under a risk of 
getting pregnant in the sixth, seventh and eighth year of trea tment.
'Overall PI', PI [INVESTIGATOR_730090] , i.e., number of pregnancies that 
occurred during the studied treatment period beyond 5 y earsdivided by  [CONTACT_730143] a risk of getting pregnant.
New text :
The primary  efficacy  variable is the occurrence of pregnancy  within y ears 6 thru 8 of Mirena 
use.However , for the analy sis after 6 y ears of Mirena use, the primary  efficacy  variabl eis the 
occurrence of pregnancy  within y ear 6 of Mirena use, and for the anal ysis after 7 y ears, the 
primary  efficacy  variable is the occurrence of pregnancy  within y ears 6 thru 7 of Mirena use. 
The PI  [INVESTIGATOR_730101] 100 woman y ears. The Pearl Index will be 
analyzed for the ‘extension treatment period’ starting at Day  1 of Year 6 of Mirena use, i.e., 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 109of 119
exposure and pregnancies between the baseline visit and Day  1 of Year 6 of Mirena use will 
be excluded. The following PIs will be calcu lated:
'1-year PI’ (sixth y ear)', PI  [INVESTIGATOR_730086], i.e., numbe r of 
pregnancies that occurred during the sixth y ear of treatment divided by  [CONTACT_730142] y ear of treatment.
'2-yearPI (sixth & seventh y ear)', PI [INVESTIGATOR_730102] y ear of 
treatment, i.e. , number of pregnancies that occurred during the sixth and seventh y ear 
of treatment divided b y time the women were under risk of getting pregnant in the 
sixth and seventh y ear of treatment.
'3-yearPI (sixth, seventh & eighth y ear)', PI [INVESTIGATOR_730103], seventh and eighth 
year of treatment, i.e., number of pregnancies that occurred during the sixth, seventh 
and eighth y ear of treatment divided by  [CONTACT_730153] a risk of getting 
pregnant in the sixth, seventh and eighth y ear of treatment.
Furthermore, the following PI [INVESTIGATOR_730089], i.e., exposure and pregnancies between the baseline visit and Day  1 of Year 6 of Mirena 
use will be included: 
'Overall PI', PI [INVESTIGATOR_730090] , i.e., number of pregnancies that 
occurred during the entire study period starting at baseline visit divided by  [CONTACT_730143] a risk of getting pregnant.
[IP_ADDRESS] Section [IP_ADDRESS] Safety variables
This section was changed as a result of Modification [IP_ADDRESS] and [IP_ADDRESS] .
Old text :
The main safet y variable is the incidence of post baseline adverse events (both serious and 
non-serious). 
Other safety  variables are: 
Uterine bleeding / Bleeding pattern 
Vital signs and weight 
Physical examin ation 
Gynecological examination 
[…]
New text :
The main safet y variable is the incidence of treatment- emergent adverse events (both serious 
and non- serious). Treatment- emergent AEs are defined as an y AEs occurring during the 
‘extension treatment period’ starting at Day  1 of Year 6 of Mirena use.
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 110of 119
Other safety  variables are: 
Uterine bleeding / Bleeding pattern 
Vital signs and weight 
[…]
[IP_ADDRESS] Section [IP_ADDRESS] Analysis of the primary variable
This section was changed as a result of Modification [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS] ,
[IP_ADDRESS] and [IP_ADDRESS] .
Old text :
The primary  variable is the occurrence of pregnancy  within y ears 6- 8 of Mirena use.
However, f or the anal ysis after 7 y ears, the primary  variable is the occurre nce of pregnancy  
within y ears 6 thru 7 of Mirena use.
New text :
The primary  variable is the occurrence of pregnancy  within y ears 6- 8 of Mirena use.
Howev er, for the anal ysis after 6 y ears, the primary  variable is the occurrence of pregnancy  
within y ears 6 of Mirena use, and for the anal ysis after 7 y ears, the primary variable is the 
occurren ce of pregnancy  within y ears 6 thru 7 of Mirena use.
[…]
Old text :
Table 10 –1 Definition of crude exposure times
PI [INVESTIGATOR_730091]/ continuation 
statusCrude exposure time
Two years
PI (sixth & 
seventh 
year)Total expulsion Date, when expulsion was realized –Baseline visit date +1
Partial Expulsion/ Mirena
removalDate of Mirena removal –Baseline visit date +1
Pregnancy Date of conception – Baseline visit date +[ADDRESS_997393] to Follow up Max (Date Mirena last known in situ –Baseline visit date +1, 0)
Continues into 8th year of 
treatment730 day s
Three years
PI (sixth, 
seventh & 
eighth 
year)Total expulsion Date, when expulsion was realized –Baseline visit date +1
Partial Expulsion/ Mirena
removalDate of Mirena removal –Baseline visit date +1
Pregnancy Date of conception – Baseline visit date +[ADDRESS_997394] to Follow up Max (Date Mirena last known in situ –Baseline visit date +1, 0)
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 111of 119
PI [INVESTIGATOR_730091]/ continuation 
statusCrude exposure time
Continues into 9th year of 
treatmentMin(1095 days, Date of EOT visit –Baseline visit date +1) 
Overall PI [INVESTIGATOR_730092], when expulsion was realized –Baseline visit date +1
Partial Expulsion/ Mirena
removalDate of Mirena removal –Baseline visit date +1
Pregnancy Date of conception – Baseline visit date +[ADDRESS_997395] to Follow up Max (Date Mirena last known in situ –Baseline visit date +1, 0)
Continued until EOT Date of EOT visit –Baseline visit date +1
A pregnancy  will be allocated to the time period(s) that are relevant for the calculation of the 
PIs described above, e.g., a pregnancy  that occurs on day  400 will be relevant for the 7thyear 
PI, the two years PI (6th and7th year), the three years PI (6th, 7th and8th y ear), and the 
overall PI. Pregnancies that 
occur after the Mirena was removed or an expulsion was realized 
will not count for an y PI.
[…]
Exposure times to be subtracted:
Subjects who apply  additional concomitant contraception are not in risk or are under a lower 
risk of getting pregnant than subjects who do not apply  additional contraception. I n case a 
subject uses concomitant contraceptive methods (e.g., condoms to prevent STD) the period of 
additional contraceptive method use will be excluded from the exposure time.
[…]
The primary  anal ysisset will be the PAS year 7 (for the anal ysis after 7 y ears) and the PAS 
year 8 (for the final anal ysis after 8 years), respectively . Furthermore, anal yses will be 
repeated for the FAS. 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 112of 119
New text :
Table 10 –1 Definition of crude exposure times –amended
PI [INVESTIGATOR_730091]/ continuation 
statusCrude exposure time
1-year PI 
(6th year)Total expulsion Date, when expulsion was discovered –Date of Day 1 Year 6 
+1
Partial Expulsion/ 
Mirena removalDate of Mirena removal –Date of Day 1 Year 6 +1
Pregnancy Date of conception – Date of Day 1 Year 6 +[ADDRESS_997396] to Follow up Maximum of (Date Mirena last known in situ –Date of Day 1 
Year 6 +1; 1 day)
Continues into 7th year 
of treatment365 day s
2-year PI 
(6th and 
7th year)Total expulsion Date, when expulsion was discovered –Date of Day 1 Year 6
+1
Partial Expulsion/ 
Mirena removalDate of Mirena removal –Date of Day 1 Year 6 +1
Pregnancy Date of conception – Date of Day 1 Year 6 +[ADDRESS_997397] to Follow up Maximum of (Date Mirena last known in situ –Date of Day 1 
Year 6 +1; 1 day )
Continues into 8th year 
of treatment730 day s
3-year PI 
(6th, 7th 
and 8th 
year)Total expulsion Date, when expulsion was discovered –Date of Day 1 Year 6
+1
Partial Expulsion/ 
Mirena removalDate of Mirena removal –Date of Day 1 Year 6 +1
Pregnancy Date of conception – Date of Day 1 Year 6 +[ADDRESS_997398] to Follow up Maximum o f (Date Mirena last known in situ –Date of Day 1 
Year 6 +1; 1 day )
Continues into 9th year 
of treatmentMinimum of(1095 days; Date of EOT visit –Date of Day 1 
Year 6 +1)
Overall PI [INVESTIGATOR_730092], when expulsion was discovered –Baseline visit date +1
Partial Expulsion/ 
Mirena removalDate of Mirena removal –Baseline visit date +1
Pregnancy Date of conception – Baseline visit date +[ADDRESS_997399] to Follow up Maximum of (Date Mirena last known in situ –Baseline visit 
date +1; 1 day )
Continued until EOT Date of EOT visit –Baseline visit date +1
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 113of 119
A pregnancy  will be allocated to the time period(s) that are rele vant for the calculation of the 
PIs described above, e.g., a pregnancy  that occurs on day  400 will be relevant for the 7thyear 
PI, the two years PI (6th and7th year), the three years PI (6th, 7th and8th y ear), and the 
overall PI. Pregnancies th at occur before Day  1 Year 6 of Mirena use will not count for the 1 -
year PI, 2- year PI [INVESTIGATOR_1238] 3 -year PI.   Pregnancies that occur after the Mirena was removed or an 
expulsion was realized will not count for any  PI.
[…]
Furthermore, it should be noted that preg nancies that occur within 7 day s after the end of 
exposure will count for the PI s. 
Exposure times to be subtracted: 
Subjects who apply  additional concomitant contraception are not in risk or are under a lower 
risk of getting pregnant than subjects who do not apply  additional contraception. I n case a 
subject uses concomitant contraceptive methods (e.g., condoms to preven t STD) the 
respective 28 -day reference period (s)of additional contraceptive method use will be excluded 
from the exposure t ime, unless a pregnancy  occurred in that 28 -day reference period . 
[…]
The primary  anal ysis set will be the PAS Year 6 (for the ana lysis after 6 y ears), the PAS Y ear 
7 (for the anal ysis after 7 y ears) and the PAS Year 8 (for the final anal ysis after 8 y ears), 
respectivel y. Furthermore, anal yses will be repeated for the FAS. 
[…]
[IP_ADDRESS] Section [IP_ADDRESS].1 Menstrual blood loss
This section wa s changed as a result of Modification [IP_ADDRESS].
Old text :
[…]
The basis for this anal ysis is the data on MBL assessed by  [CONTACT_112744] (see 
section 9.4.2). If a woman has documented in the eDiary  (see section 9.7.1) that no bleeding 
occurred during one of the considered 30-day time periods for collection of sanitary  
protection , the MBL will be assumed to be zero in that time period.
This analy sis will be conducted in the FAS in the subgroup ofwomen who had Mirena 
inserted for HMB.
New text :
[…]
The basis for this anal ysis is the data on MBL assessed by  [CONTACT_112744] (see 
section 9.4.2). If a woman has documented in the eDiary  (see section 9.7.1) that no bleeding 
occurred during one of the 30 -day time periods considered for coll ection of sanitary  products, 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 114of 119
the MBL will be assumed to be zero in that time period. The handling of partial or missing 
data (i.e. data on sanitary products and/or bleeding intensities) and detailed imputation rules 
will be described in the statistical ana lysis plan. 
This analy sis will be conducted in the FAS in the HMB subgroup, i.e. women who had 
Mirena inserted for both contraception and HMB .
[…]
[IP_ADDRESS] Section [IP_ADDRESS].2 Categorized menstrual blood loss (MBL) (<80ml / 30 
days)
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
No clinical change in bleeding profile regarding HMB will be concluded if the volume of 
blood loss remains < 80mL  during the end of y ears 6, 7 and 8. Therefore, the proportion of 
women with an MBL <80 mL  / 30 day s will analyzed.  Descriptive statistics as well as 95% 
Clopper -Pearson confidence intervals will be provided for each of the time periods in which 
HMB is assessed. Success will be concluded regarding this endpoint if less than 20% of the 
women included in to the study  for HMB have a clinical change in bleeding profile (according 
to the definition above) .
This analy sis will be conducted in the FAS in the subgroup of women who had Mirena 
inserted for HMB.
New text :
No clinical change in bleeding profile rega rding HMB after Year 5 until the end of Year 6, 
until the end of Year 7 and until the end of Year 8, respectivel y, will be concluded if the 
volume of blood loss was< 80mL at the beginning of Year 6 and remained < 80mL  atthe end 
of Years 6, 7 and 8 , respe ctively . Vice versa, clinical change in bleeding profile regarding 
HMB after Year 5 until the end of Year 6, end of Year 7 and end of Year 8, respectivel y, will 
be concluded if the volume of blood loss was ≥ 80mL  at the beginning of Year 6 or at end of 
Years 6, 7 or 8, respectively .
Therefore, the proportion of women with clinical change in bleeding profile regarding HMB 
will be analyzed.  Descriptive statistics as well as 95% Clopper- Pearson confidence intervals 
will be provided. 
For the anal ysis after 6 years, the proportion of women with clinical change in bleeding 
profile regarding HMB after Year 5 until the end of Year 6 will be analyzed. 
For the anal ysis after 6 years, the following women will constitute the denominator: 
Baseline MBL>80mL/30day s, or 
Baseline MBL not >80mL/30day s and 
End of Year 6 MBL assessment available. 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 115of 119
That means, women with Baseline MBL not >80mL/30day s and MBL assessment at the end 
of Year [ADDRESS_997400] to 
follow up without preceding clinical change in bleeding profile regarding HMB. 
For the anal ysis after 6 years, the following women will constitute the nominator: 
Baseline MBL>80mL/30day s, or 
End of Year 6 MBL>80mL /30day s. 
For the anal ysis after 7 years, the proportion of women with clinical change in bleeding 
profile regarding HMB after Year 5 until the end of Year 7 will be analyzed. 
For the anal ysis after 7 years, the following women will constitute the denominator: 
Baseline MBL>80mL/30day s, or 
End of Year 6 MBL>80mL /30day s, or 
Baseline MBL not >80mL/30day s and 
End of Year 6 MBL not >80mL /30day s and 
End of Year 7 MBL assessment available. 
That means, women with Baseline MBL not >80mL/30day s, MBL at the end of Year 6 not 
>80mL /30day s and MBL assessment at the end of Year [ADDRESS_997401] to follow up without preceding clinical change in 
bleeding profile regarding HMB. 
For the anal ysis after 7 years, th e following women will constitute the nominator: 
Baseline MBL>80mL/30day s, or 
End of Year 6 MBL>80mL /30day s, or 
End of Year 7 MBL>80mL /30day s.
For the final anal ysis after 8 y ears, the proportion of women with clinical change in bleeding 
profile regardi ng HMB after Year 5 until the end of Year 8 will be analyzed. 
For the anal ysis after 8 years, the following women will constitute the denominator: 
Baseline MBL>80mL/30day s, or 
End of Year 6 MBL>80mL /30day s, or 
End of Year 7 MBL>80mL /30day s, or 
Baselin e MBL not >80mL/30day s and 
End of Year 6 MBL not >80mL /30day s and 
End of Year 7 MBL not >80mL /30day s and 
End of Year 8 MBL assessment available. 
That means, women with Baseline MBL not >80mL/30day s, MBL at the end of Year 6 not 
>80mL /30day s, MBL at the end of Year 7 not >80mL /30day s and MBL assessment at the end 
of Year [ADDRESS_997402] to 
follow up without preceding clinical change in bleeding profile regarding HMB. 
For the anal ysis aft er 8 years, the following women will constitute the nominator: 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 116of 119
Baseline MBL>80mL/30day s, or 
End of Year 6 MBL>80mL /30day s, or 
End of Year 7 MBL>80mL /30day s, or 
End of Year 8 MBL>80mL /30day s. 
Success will be concluded regarding this endpoint if less than 20% of the women in the HMB
subgroup have a clinical change in bleeding profile regarding HMB (according to the 
definition ab ove) and the upper limit of the corresponding 95% Clopper-Pearson co nfidence 
interval is equal to or less than 35%.
This analy sis will be conducted in the FAS in the HMB subgroup, i.e. women who had 
Mirena inserted fo r both contraception and HMB.
[IP_ADDRESS] Section [IP_ADDRESS] Analysis of safety variables
This section was changed as a result of Modification [IP_ADDRESS] and [IP_ADDRESS] .
Old text :
All safet y variables will be anal yzed based on the SAF.
The main safet y variable is the incidence of post baseline adverse events (both serious and 
non-serious).
New text :
All safet y variables will be anal yzed based on the SAF.
The main safet y variable is the in cidence of treatment- emergent adverse events (both serious 
and non- serious) .Treatment- emergent AEs are defined as an y AEs occurring during the 
‘extension treatment period’ starting at Day  1 of Year 6 of Mirena use.
[IP_ADDRESS] Section [IP_ADDRESS].2 Bleeding pattern
This section was changed as a result of Modification [IP_ADDRESS] , [IP_ADDRESS] and [IP_ADDRESS] .
Old text :
Bleeding diary  data will be anal yzed according to the sponsor’s Best 
practice entitled 
“Recording and evaluation of bleeding data”.
[…]
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 117of 119
Table 10 –2 Bleeding Intensity Codes and WHO Definitions for Bleeding Intensity
Bleeding Intensity
CodesWHO Definitions
3 - 5 Bleeding/spotting epi[INVESTIGATOR_1865]: Day(s) with bleeding/spotting preceded 
and followed by  [CONTACT_2669] 2 bleeding -free 
days.
2 Spotting -only epi[INVESTIGATOR_1865]: Day(s) with spotting preceded and followed 
by [CONTACT_2669] 2 bleeding -free days.
1 Bleeding/spotting -free interval: At least 2 days without bleeding/spotting 
preceded and followed by [CONTACT_2669] 1 
bleeding/spotting day.
[…]
Based on daily  data obtained from the electronic diary , the bleeding pattern will be reported 
using reference periods of [ADDRESS_997403] 28-day and 90-day reference period, 
respectivel y, will start at the baseline visit (Visit 2) .  For each subject and for each period, the 
number of bleeding/spotting day s and bleeding/spotting epi[INVESTIGATOR_730104].[…]
New text :
Bleeding diary  data during the ‘extension treatment period’ starting at Day  1 of Year 6 of 
Mirena use will be anal yzed according to the sponsor’s Best Practice Document entitled 
“Recording and evaluation of bleeding data”. Bleeding diary  data prior to the ‘extension 
treatment period’ will not be included in the anal yses. The handling of partial or missing data 
and detailed imputation rules will be described in the statistical analysis plan.
[…]
Table 10 –2 Bleeding Intensity Codes and WHO Definitions for Bleeding Intensity –
amended 
Bleeding Intensity
CodesWHO Definitions
2 - 5 Bleeding/spotting epi[INVESTIGATOR_1865]: Day(s) with bleeding/spotting preceded 
and followed by [CONTACT_2669] 2 bleeding -free 
days.
2 Spotting -only epi[INVESTIGATOR_1865]: Day(s) with spotting preceded and followed 
by [CONTACT_2669] 2 bleeding -free days.
1 Bleeding/spotting -free interval: At least 2 days without bleeding/spotting 
preceded and followed by [CONTACT_2669] 1 
bleeding/spotting day.
[…]
Based on daily  data obtained from the electronic diary , the bleeding pattern will be reported 
using reference periods of [ADDRESS_997404] 28-day and 90-day reference period, 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 118of [ADDRESS_997405] and for each 
period, the number of bleeding/spotting day s and bleeding/spotting epi[INVESTIGATOR_615901]. […]
[IP_ADDRESS] Section 10.5 Planned interim analyses
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
No formal interim anal ysis in the sense of a group sequential or adaptive design is planned. 
However, an anal ysis of the data is planned after y ear 7, including all subjects who have 
prematurel y discontinued or completed Visit 6, i.e. treated with Mirena f or up to 7 y ears (2 
years in the study ).
New text :
No formal interim anal ysis in the sense of a group sequential or adaptive design is planned. 
Howe ver, an anal ysis of the data is planned after Year 6, including all subjects who have 
prematurel y discontinued or completed Visit 4, i.e. treated with Mirena for up to 6 y ears 
(1year in the stud y). Another analysis of the data is planned after Y ear 7, including all 
subjects who have prematurely  discontinued or completed Visit 6, i.e. treated with Mirena for 
upto 7 y ears(2 years in the study ).
[IP_ADDRESS] Section 11.1 Data re cording
This section was changed as a result of Modification [IP_ADDRESS] 3.
Old text :
The data collection tool for this study  will be eCRF; a validated electronic data capture s ystem 
called RAVE.  Subjec t data necessary  for analy sis and reporting will be entered/transmitted 
into a validated database or data s ystem (CIE/TOSCA; SAS).  
Covance will perform the data entry  for this study.
  Data will be entered b ysite personnel into 
aninternet based electron ic data capture software sy stem RAVE, which Covance has licensed 
from Medidata Solutions Worldwide. RAVE has been validated b y Medidata Solutions 
Worldwide and Covance for use in its clinical studies.  […]
New text :
The data collection tool for this study  will be eCRF; a validated electronic data capture s ystem 
called RAVE.  Subject data necessary  for analy sis and reporting will be entered/transmitted 
into a validated database or data system ( e.g.CIE/TOSCA; SAS).  
Data will be entered b ysite personnel into an internet based electronic data capture software 
system RAVE, which Covance has licensed from Medidata Solutions Worldwide. RAVE has 
Clinical Study  Protocol
No.  BAY86 -5028 / [ZIP_CODE]
20SEP 2017 Version 2.0 Page: 119of 119
been validated b y Medidata Solutions Worldwide and Covance for use in its clinical studies.  
[…]
[IP_ADDRESS] Section 13.1 Investigators and other study personnel
New text added :
The name [CONTACT_3669] [CONTACT_31036]’s Study Medical Expert [INVESTIGATOR_730154] 1.  The co -ordinating investigator who will be responsible for signing t he CSR, is 
 (study  center #   All other study  personnel not included in 
this section are identified in a separate personnel list (not part of this clinical study  protocol) 
as appropriate. […]
[IP_ADDRESS] Section [ADDRESS_997406]
This section was changed as a result of Modification [IP_ADDRESS].
Old text :
1. Rowe P, Farley  T, Peregoudov A, Pi[INVESTIGATOR_25192] G, Boccard S, Landoulsi S, Meirik O; IUD 
Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of 
Research; Development and Research Training in Human Reproduction. Safet y and 
efficacy  in parous women of a 52 -mg levonorgestrel -
medicated intrauterine device: a 
7-year randomized comparative study  with the TCu380A. Contraception. 2016 
Jun;93(6):498 -506. doi: 10.1016/j.contraception.2016.0 2.024. Epub 2016 Feb 23.
2. Sivin I , Stern J, Coutinho E, Mattos CER, El Mahgoub S, Diaz S et al. Prolonged 
intrauterine contraception: a seven -year randomized study  of the levonorgestrel 20 
mcg/day  (LNG 20) and the Copper T380 Ag IUDS. Contraception 1991; 44:473 -
80.
New text :
1. McNicholas C, Swor E, Wan L , Peipert JF. Prolonged use of the etonogestrel implant 
and levonorgestrel intrauterine device: 2 y ears beyond Food and Drug Administration -
approved duration. Am J Obstet Gy necol. 2017 Jan 29[Epub ahead of print].
2. Rowe P, Farley  T, Peregoudov A, Pi[INVESTIGATOR_25192] G, Boccard S, Landoulsi S, Meirik O; IUD 
Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of 
Research; Development and Research Training in Human Reproduction. Safet y and 
efficacy  in pa rous women of a 52 -mg levonorgestrel -medicated intrauterine device: a 
7-year randomized compa rative stud y with the TCu380A. Contraception. 2016 
Jun;93(6):498 -506. doi: 10.1016/j.contraception.2016.02.024. Epub 2016 Feb 23.
3. Sivin I , Stern J, Coutinho E, 
Mattos CER, El Mahgoub S, Diaz S et al. Prolonged 
intrauterine contraception: a seven -year randomized study  of the levonorgestrel 20 
mcg/day  (LNG 20) and the Copper T380 Ag IUDS. Contraception 1991;44:473-80.
[COMPANY_003]
[COMPANY_003]